https://trial.medpath.com/news/assessing-phase-2-data-on-bepranemab-s-effect-on-tau-accumulation-and-cognitive-function 2024-11-07T18:10:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/assessing-phase-2-data-on-bepranemab-s-effect-on-tau-accumulation-and-cognitive-function 2024-11-07T18:10:43+00:00 weekly 0.7 https://trial.medpath.com/news/kwality-pharma-received-approval-for-leuprorelin-acetate-for-injectable-suspension-from-greece 2024-11-07T17:41:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kwality-pharma-received-approval-for-leuprorelin-acetate-for-injectable-suspension-from-greece 2024-11-07T17:41:22+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-align-trial-shows-atrasentan-significantly-reduces-proteinuria-in-high-risk-iga 2024-11-07T17:38:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-align-trial-shows-atrasentan-significantly-reduces-proteinuria-in-high-risk-iga 2024-11-07T17:38:56+00:00 weekly 0.7 https://trial.medpath.com/news/ema-accepts-marketing-authorization-application-for-alvotech-s-avt05-golimumab 2024-11-07T17:37:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-accepts-marketing-authorization-application-for-alvotech-s-avt05-golimumab 2024-11-07T17:37:37+00:00 weekly 0.7 https://trial.medpath.com/news/review-clinical-trials-show-cannabis-improves-symptoms-in-fibromyalgia-patients 2024-11-07T17:26:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/review-clinical-trials-show-cannabis-improves-symptoms-in-fibromyalgia-patients 2024-11-07T17:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-suggests-removing-oral-phenylephrine-as-otc-monograph-nasal-decongestant-ingredient 2024-11-07T17:23:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-suggests-removing-oral-phenylephrine-as-otc-monograph-nasal-decongestant-ingredient 2024-11-07T17:23:16+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-s-disease-clinical-research-in-7mm-focuses-on-disease-modifying-agents 2024-11-07T17:19:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/parkinson-s-disease-clinical-research-in-7mm-focuses-on-disease-modifying-agents 2024-11-07T17:19:44+00:00 weekly 0.7 https://trial.medpath.com/news/study-explores-underpinnings-of-immunotherapy-releated-myocarditis-in-patients-with-cancer 2024-11-07T17:15:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-explores-underpinnings-of-immunotherapy-releated-myocarditis-in-patients-with-cancer 2024-11-07T17:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-wins-fda-approval-for-varipulse-pfa-system-medtech-dive 2024-11-07T17:09:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-wins-fda-approval-for-varipulse-pfa-system-medtech-dive 2024-11-07T17:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-mb-108-for-malignant-glioma-onclive 2024-11-07T17:08:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-mb-108-for-malignant-glioma-onclive 2024-11-07T17:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/minghui-pharmaceutical-s-mhb039a-shows-promise-in-phase-i-trial-for-solid-tumours 2024-11-07T16:53:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minghui-pharmaceutical-s-mhb039a-shows-promise-in-phase-i-trial-for-solid-tumours 2024-11-07T16:53:42+00:00 weekly 0.7 https://trial.medpath.com/news/transgene-and-nec-present-new-data-confirming-clinical-globenewswire 2024-11-07T16:51:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transgene-and-nec-present-new-data-confirming-clinical-globenewswire 2024-11-07T16:51:09+00:00 weekly 0.7 https://trial.medpath.com/news/designing-inclusive-clinical-trials-in-an-effort-to-upend-the-hiv-epidemic-gilead-sciences 2024-11-07T16:42:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/designing-inclusive-clinical-trials-in-an-effort-to-upend-the-hiv-epidemic-gilead-sciences 2024-11-07T16:42:05+00:00 weekly 0.7 https://trial.medpath.com/news/emrosi-new-rosacea-treatment-option-approved-by-the-fda-webmd 2024-11-07T16:32:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emrosi-new-rosacea-treatment-option-approved-by-the-fda-webmd 2024-11-07T16:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-discontinues-next-generation-duchenne-drugs-stat-news 2024-11-07T16:30:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarepta-discontinues-next-generation-duchenne-drugs-stat-news 2024-11-07T16:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/padeliporfin-vtp-maintains-robust-responses-and-is-safe-in-low-grade-upper-tract 2024-11-07T16:23:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/padeliporfin-vtp-maintains-robust-responses-and-is-safe-in-low-grade-upper-tract 2024-11-07T16:23:17+00:00 weekly 0.7 https://trial.medpath.com/news/senhwa-biosciences-starts-trial-of-silmitasertib-in-children-with-difficult-to-treat-cancers 2024-11-07T16:12:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senhwa-biosciences-starts-trial-of-silmitasertib-in-children-with-difficult-to-treat-cancers 2024-11-07T16:12:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-places-clinical-hold-on-epilepsy-agent-rap-219-for-diabetic-peripheral-neuropathic-pain 2024-11-07T16:06:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-places-clinical-hold-on-epilepsy-agent-rap-219-for-diabetic-peripheral-neuropathic-pain 2024-11-07T16:06:37+00:00 weekly 0.7 https://trial.medpath.com/news/eque-cel-car-t-shows-strong-results-for-multiple-myeloma 2024-11-07T16:03:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eque-cel-car-t-shows-strong-results-for-multiple-myeloma 2024-11-07T16:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-enlighted-trial-padeliporfin-vtp-shows-promise-in-low-grade-utuc 2024-11-07T16:03:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-enlighted-trial-padeliporfin-vtp-shows-promise-in-low-grade-utuc 2024-11-07T16:03:26+00:00 weekly 0.7 https://trial.medpath.com/news/schizophrenia-pharmacology-version-2-0-psychiatric-times 2024-11-07T16:02:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/schizophrenia-pharmacology-version-2-0-psychiatric-times 2024-11-07T16:02:53+00:00 weekly 0.7 https://trial.medpath.com/news/sitc-study-finds-io102-io103-vaccine-plus-pembrolizumab-active-in-patients-with-non 2024-11-07T15:46:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sitc-study-finds-io102-io103-vaccine-plus-pembrolizumab-active-in-patients-with-non 2024-11-07T15:46:59+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-announces-long-term-efficacy-and-safety-data-from-phase-3 2024-11-07T15:42:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/springworks-therapeutics-announces-long-term-efficacy-and-safety-data-from-phase-3 2024-11-07T15:42:23+00:00 weekly 0.7 https://trial.medpath.com/news/postoperative-tumor-bed-radiation-versus-t-shaped-field-radiation-in-the-treatment-of-locally 2024-11-07T15:40:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/postoperative-tumor-bed-radiation-versus-t-shaped-field-radiation-in-the-treatment-of-locally 2024-11-07T15:40:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-varipulse-platform-for-treatment-of-atrial-fibrillation-hcplive 2024-11-07T15:37:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-varipulse-platform-for-treatment-of-atrial-fibrillation-hcplive 2024-11-07T15:37:52+00:00 weekly 0.7 https://trial.medpath.com/news/ema-approves-sanofi-regeneron-s-dupixent-for-young-eoe-patients-yahoo 2024-11-07T15:33:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-approves-sanofi-regeneron-s-dupixent-for-young-eoe-patients-yahoo 2024-11-07T15:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/u-k-study-shows-most-cancer-patients-would-benefit-from-pharmacogenetic-testing 2024-11-07T15:30:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-k-study-shows-most-cancer-patients-would-benefit-from-pharmacogenetic-testing 2024-11-07T15:30:20+00:00 weekly 0.7 https://trial.medpath.com/news/uganda-phase-ii-of-mass-polio-vaccination-kicks-off-allafrica-com 2024-11-07T15:29:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uganda-phase-ii-of-mass-polio-vaccination-kicks-off-allafrica-com 2024-11-07T15:29:53+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-discontinues-development-of-duchenne-aso-treatment-vesleteplirsen 2024-11-07T15:28:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarepta-discontinues-development-of-duchenne-aso-treatment-vesleteplirsen 2024-11-07T15:28:08+00:00 weekly 0.7 https://trial.medpath.com/news/nektar-and-collaborators-present-late-breaking-results-from-phase-2-study-of-nktr-255 2024-11-07T15:19:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nektar-and-collaborators-present-late-breaking-results-from-phase-2-study-of-nktr-255 2024-11-07T15:19:49+00:00 weekly 0.7 https://trial.medpath.com/news/nimbus-therapeutics-presents-positive-updated-data-from-phase-1-2-clinical-trial-of-hpk1 2024-11-07T15:17:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nimbus-therapeutics-presents-positive-updated-data-from-phase-1-2-clinical-trial-of-hpk1 2024-11-07T15:17:34+00:00 weekly 0.7 https://trial.medpath.com/news/enfortumab-vedotin-plus-pembrolizumab-leads-to-shifts-in-frontline-metastatic-urothelial 2024-11-07T15:08:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enfortumab-vedotin-plus-pembrolizumab-leads-to-shifts-in-frontline-metastatic-urothelial 2024-11-07T15:08:18+00:00 weekly 0.7 https://trial.medpath.com/news/imunon-presents-positive-data-from-phase-2-ovation-2-globenewswire 2024-11-07T15:08:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imunon-presents-positive-data-from-phase-2-ovation-2-globenewswire 2024-11-07T15:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/emergent-biosolutions-supports-new-clinical-trial-evaluating-the-safety-and-efficacy-biospace 2024-11-07T15:02:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emergent-biosolutions-supports-new-clinical-trial-evaluating-the-safety-and-efficacy-biospace 2024-11-07T15:02:31+00:00 weekly 0.7 https://trial.medpath.com/news/oculis-reports-q3-2024-financial-results-and-provides-company-updates 2024-11-07T15:01:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oculis-reports-q3-2024-financial-results-and-provides-company-updates 2024-11-07T15:01:22+00:00 weekly 0.7 https://trial.medpath.com/news/vidac-pharma-receives-reinvestment-from-shareholders-to-drive-clinical-trials-of-its-cancer 2024-11-07T14:59:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vidac-pharma-receives-reinvestment-from-shareholders-to-drive-clinical-trials-of-its-cancer 2024-11-07T14:59:32+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-halts-development-of-next-gen-dmd-drug-reports-robust-elevidys-sales 2024-11-07T14:58:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarepta-halts-development-of-next-gen-dmd-drug-reports-robust-elevidys-sales 2024-11-07T14:58:05+00:00 weekly 0.7 https://trial.medpath.com/news/tacrolimus-linked-to-lower-acute-gvhd-risk-american-journal-of-managed-care 2024-11-07T14:50:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tacrolimus-linked-to-lower-acute-gvhd-risk-american-journal-of-managed-care 2024-11-07T14:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/impact-biotech-presents-updated-interim-phase-3-data-from-enlighted-study-of-biospace 2024-11-07T14:45:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-biotech-presents-updated-interim-phase-3-data-from-enlighted-study-of-biospace 2024-11-07T14:45:54+00:00 weekly 0.7 https://trial.medpath.com/news/palvella-therapeutics-announces-first-patient-dosed-in-selva-phase-3-clinical-trial-biospace 2024-11-07T14:45:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palvella-therapeutics-announces-first-patient-dosed-in-selva-phase-3-clinical-trial-biospace 2024-11-07T14:45:45+00:00 weekly 0.7 https://trial.medpath.com/news/quoin-pharmaceuticals-provides-corporate-update-and-announces-third-quarter-2024 2024-11-07T14:45:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quoin-pharmaceuticals-provides-corporate-update-and-announces-third-quarter-2024 2024-11-07T14:45:42+00:00 weekly 0.7 https://trial.medpath.com/news/rallybio-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-07T14:45:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rallybio-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-07T14:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/applied-therapeutics-reports-third-quarter-2024-financial-results-biospace 2024-11-07T14:45:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/applied-therapeutics-reports-third-quarter-2024-financial-results-biospace 2024-11-07T14:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-mb-108-hsv-1-biospace 2024-11-07T14:45:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-mb-108-hsv-1-biospace 2024-11-07T14:45:02+00:00 weekly 0.7 https://trial.medpath.com/news/pepgen-inc-sec-10-q-report-tradingview 2024-11-07T14:43:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pepgen-inc-sec-10-q-report-tradingview 2024-11-07T14:43:51+00:00 weekly 0.7 https://trial.medpath.com/news/pmv-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-11-07T14:43:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pmv-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-11-07T14:43:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-lbl-034-in-multiple-myeloma-targeted-oncology 2024-11-07T14:42:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-lbl-034-in-multiple-myeloma-targeted-oncology 2024-11-07T14:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/fda-to-decide-on-spn-830-apomorphine-pump-approval-feb-1-parkinson-s-news-today 2024-11-07T14:33:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-to-decide-on-spn-830-apomorphine-pump-approval-feb-1-parkinson-s-news-today 2024-11-07T14:33:19+00:00 weekly 0.7 https://trial.medpath.com/news/pharmala-to-supply-laneo-mdma-for-clinical-trial-at-yale-globenewswire 2024-11-07T14:31:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmala-to-supply-laneo-mdma-for-clinical-trial-at-yale-globenewswire 2024-11-07T14:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/ryvu-therapeutics-reports-2024-q3-financial-results-and-provides-corporate-update 2024-11-07T14:31:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ryvu-therapeutics-reports-2024-q3-financial-results-and-provides-corporate-update 2024-11-07T14:31:18+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-medtech-wins-fda-nod-for-varipulse-pfa-massdevice 2024-11-07T14:26:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-medtech-wins-fda-nod-for-varipulse-pfa-massdevice 2024-11-07T14:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-how-cancer-immunotherapy-leads-to-deadly-form-of-heart-inflammation-in 2024-11-07T14:22:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-how-cancer-immunotherapy-leads-to-deadly-form-of-heart-inflammation-in 2024-11-07T14:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/rome-therapeutics-to-present-data-supporting-line-1-reverse-transcriptase-inhibitors-as 2024-11-07T14:19:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rome-therapeutics-to-present-data-supporting-line-1-reverse-transcriptase-inhibitors-as 2024-11-07T14:19:32+00:00 weekly 0.7 https://trial.medpath.com/news/addressing-informative-censoring-bias-in-clinical-trials-targeted-oncology 2024-11-07T14:07:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addressing-informative-censoring-bias-in-clinical-trials-targeted-oncology 2024-11-07T14:07:43+00:00 weekly 0.7 https://trial.medpath.com/news/adipo-therapeutics-presents-positive-study-results-about-potential-obesity-treatment-news 2024-11-07T14:01:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adipo-therapeutics-presents-positive-study-results-about-potential-obesity-treatment-news 2024-11-07T14:01:15+00:00 weekly 0.7 https://trial.medpath.com/news/oculis-reports-q3-2024-financial-results-and-provides-company-updates-markets-insider 2024-11-07T13:59:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oculis-reports-q3-2024-financial-results-and-provides-company-updates-markets-insider 2024-11-07T13:59:48+00:00 weekly 0.7 https://trial.medpath.com/news/how-improvements-in-us-fda-regulatory-process-and-procedures-led-to-the-drug-approval 2024-11-07T13:58:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-improvements-in-us-fda-regulatory-process-and-procedures-led-to-the-drug-approval 2024-11-07T13:58:24+00:00 weekly 0.7 https://trial.medpath.com/news/driving-pan-african-research-collaboration-panther-and-africa-cdc-launch-the-mpox 2024-11-07T13:52:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/driving-pan-african-research-collaboration-panther-and-africa-cdc-launch-the-mpox 2024-11-07T13:52:55+00:00 weekly 0.7 https://trial.medpath.com/news/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-mb-108-hsv-1-oncolytic 2024-11-07T13:51:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-mb-108-hsv-1-oncolytic 2024-11-07T13:51:35+00:00 weekly 0.7 https://trial.medpath.com/news/palisade-bio-launches-phase-1-trial-for-novel-ulcerative-colitis-drug-pali-2108 2024-11-07T13:39:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palisade-bio-launches-phase-1-trial-for-novel-ulcerative-colitis-drug-pali-2108 2024-11-07T13:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-nears-alzheimer-s-drug-trial-results-investing-com 2024-11-07T13:38:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cassava-sciences-nears-alzheimer-s-drug-trial-results-investing-com 2024-11-07T13:38:58+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-beats-q3-expectations-fueled-by-hiv-drug-sales-raises-full-year-guidance 2024-11-07T13:37:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-beats-q3-expectations-fueled-by-hiv-drug-sales-raises-full-year-guidance 2024-11-07T13:37:08+00:00 weekly 0.7 https://trial.medpath.com/news/q32-bio-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-07T13:36:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q32-bio-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-07T13:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-antibody-drug-conjugates-market-drugs-approval-price-sales-clinical-trials 2024-11-07T13:21:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-antibody-drug-conjugates-market-drugs-approval-price-sales-clinical-trials 2024-11-07T13:21:10+00:00 weekly 0.7 https://trial.medpath.com/news/lung-cancer-awareness-month-2024-looking-back-at-progress-for-cell-and-gene-therapy 2024-11-07T13:20:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lung-cancer-awareness-month-2024-looking-back-at-progress-for-cell-and-gene-therapy 2024-11-07T13:20:21+00:00 weekly 0.7 https://trial.medpath.com/news/lakeshore-biopharma-initiates-biologics-license-application-of-pika-rabies-vaccine-to-the 2024-11-07T13:18:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lakeshore-biopharma-initiates-biologics-license-application-of-pika-rabies-vaccine-to-the 2024-11-07T13:18:04+00:00 weekly 0.7 https://trial.medpath.com/news/quoin-pharmaceuticals-provides-corporate-update-and-announces-third-quarter-2024 2024-11-07T13:17:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quoin-pharmaceuticals-provides-corporate-update-and-announces-third-quarter-2024 2024-11-07T13:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/cel-sci-s-cancer-drug-shows-73-survival-rate-fda-agrees-on-pd-l1-biomarker-use 2024-11-07T13:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cel-sci-s-cancer-drug-shows-73-survival-rate-fda-agrees-on-pd-l1-biomarker-use 2024-11-07T13:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/rome-therapeutics-to-present-data-supporting-line-1-reverse-globenewswire 2024-11-07T13:12:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rome-therapeutics-to-present-data-supporting-line-1-reverse-globenewswire 2024-11-07T13:12:32+00:00 weekly 0.7 https://trial.medpath.com/news/magea4-opens-the-door-for-engineered-cellular-therapies-in-solid-tumors-onclive 2024-11-07T13:08:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/magea4-opens-the-door-for-engineered-cellular-therapies-in-solid-tumors-onclive 2024-11-07T13:08:14+00:00 weekly 0.7 https://trial.medpath.com/news/imunon-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-07T13:07:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imunon-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-07T13:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-medtech-receives-fda-approval-for-the-varipulsetm-pulsed-field 2024-11-07T13:05:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-medtech-receives-fda-approval-for-the-varipulsetm-pulsed-field 2024-11-07T13:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/movano-health-announces-completion-of-clinical-study-with-cuffless-rf-blood-pressure-device 2024-11-07T13:00:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/movano-health-announces-completion-of-clinical-study-with-cuffless-rf-blood-pressure-device 2024-11-07T13:00:44+00:00 weekly 0.7 https://trial.medpath.com/news/xoma-royalty-reports-third-quarter-2024-financial-results-and-highlights-recent-activities 2024-11-07T12:57:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xoma-royalty-reports-third-quarter-2024-financial-results-and-highlights-recent-activities 2024-11-07T12:57:17+00:00 weekly 0.7 https://trial.medpath.com/news/rapport-therapeutics-reports-third-quarter-financials-and-provides-business-update 2024-11-07T12:47:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapport-therapeutics-reports-third-quarter-financials-and-provides-business-update 2024-11-07T12:47:47+00:00 weekly 0.7 https://trial.medpath.com/news/castle-boasts-melanoma-test-s-capacity-to-reduce-unnecessary-testing-clinical-trials-arena 2024-11-07T12:41:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/castle-boasts-melanoma-test-s-capacity-to-reduce-unnecessary-testing-clinical-trials-arena 2024-11-07T12:41:42+00:00 weekly 0.7 https://trial.medpath.com/news/moonlake-immunotherapeutics-sec-10-q-report-tradingview 2024-11-07T12:40:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moonlake-immunotherapeutics-sec-10-q-report-tradingview 2024-11-07T12:40:33+00:00 weekly 0.7 https://trial.medpath.com/news/olanzapine-for-young-people-with-anorexia-nervosa-open-results-of-a-feasibility-study 2024-11-07T12:40:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/olanzapine-for-young-people-with-anorexia-nervosa-open-results-of-a-feasibility-study 2024-11-07T12:40:28+00:00 weekly 0.7 https://trial.medpath.com/news/xoma-royalty-reports-third-quarter-2024-financial-results-and-highlights-recent-activities 2024-11-07T12:33:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xoma-royalty-reports-third-quarter-2024-financial-results-and-highlights-recent-activities 2024-11-07T12:33:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-ablas-for-prolia-r-xgeva-r-biosimilars-from-organon-and-teva-mondaq 2024-11-07T12:32:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-ablas-for-prolia-r-xgeva-r-biosimilars-from-organon-and-teva-mondaq 2024-11-07T12:32:05+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-regeneron-s-dupixent-approved-by-ec-for-younger-eosinophilic-oesophagitis-patients 2024-11-07T12:27:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-regeneron-s-dupixent-approved-by-ec-for-younger-eosinophilic-oesophagitis-patients 2024-11-07T12:27:18+00:00 weekly 0.7 https://trial.medpath.com/news/eton-pharmaceuticals-awarded-second-patent-for-et-400-hydrocortisone-oral-solution 2024-11-07T12:22:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eton-pharmaceuticals-awarded-second-patent-for-et-400-hydrocortisone-oral-solution 2024-11-07T12:22:47+00:00 weekly 0.7 https://trial.medpath.com/news/amylyx-pharmaceuticals-reports-third-quarter-2024-financial-results-morningstar 2024-11-07T12:21:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amylyx-pharmaceuticals-reports-third-quarter-2024-financial-results-morningstar 2024-11-07T12:21:15+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-showcases-strength-of-hematology-portfolio-and-pipeline-at-ash-2024 2024-11-07T12:21:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-showcases-strength-of-hematology-portfolio-and-pipeline-at-ash-2024 2024-11-07T12:21:14+00:00 weekly 0.7 https://trial.medpath.com/news/eu-approves-dupixent-for-treating-eosinophilic-esophagitis-in-young-children 2024-11-07T12:20:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-approves-dupixent-for-treating-eosinophilic-esophagitis-in-young-children 2024-11-07T12:20:29+00:00 weekly 0.7 https://trial.medpath.com/news/impact-biotech-presents-updated-interim-phase-3-data-from-enlighted-study-of-morningstar 2024-11-07T12:13:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-biotech-presents-updated-interim-phase-3-data-from-enlighted-study-of-morningstar 2024-11-07T12:13:13+00:00 weekly 0.7 https://trial.medpath.com/news/impact-biotech-presents-updated-interim-phase-3-data-from-globenewswire 2024-11-07T12:11:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-biotech-presents-updated-interim-phase-3-data-from-globenewswire 2024-11-07T12:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/rapport-therapeutics-reports-third-quarter-financials-and-provides-business-update 2024-11-07T12:11:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapport-therapeutics-reports-third-quarter-financials-and-provides-business-update 2024-11-07T12:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/applied-therapeutics-reports-third-quarter-2024-financial-results-globenewswire 2024-11-07T12:10:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/applied-therapeutics-reports-third-quarter-2024-financial-results-globenewswire 2024-11-07T12:10:15+00:00 weekly 0.7 https://trial.medpath.com/news/drug-giants-display-advanced-technologies-solutions-at-ciie-chinadaily-com-cn 2024-11-07T11:57:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-giants-display-advanced-technologies-solutions-at-ciie-chinadaily-com-cn 2024-11-07T11:57:17+00:00 weekly 0.7 https://trial.medpath.com/news/immunic-inc-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-07T11:39:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunic-inc-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-07T11:39:59+00:00 weekly 0.7 https://trial.medpath.com/news/immunic-inc-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-07T11:36:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunic-inc-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-07T11:36:16+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-secures-30-million-in-debt-funding-globenewswire 2024-11-07T11:35:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-secures-30-million-in-debt-funding-globenewswire 2024-11-07T11:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/arbutus-biopharma-corp-abus-q3-2024-earnings-call-highlights-promising-clinical-trials-and 2024-11-07T11:33:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arbutus-biopharma-corp-abus-q3-2024-earnings-call-highlights-promising-clinical-trials-and 2024-11-07T11:33:19+00:00 weekly 0.7 https://trial.medpath.com/news/senhwa-enrols-first-subject-in-phase-i-ii-trial-of-silmitasertib-for-solid-tumours 2024-11-07T11:21:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senhwa-enrols-first-subject-in-phase-i-ii-trial-of-silmitasertib-for-solid-tumours 2024-11-07T11:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/cerebral-near-infrared-spectroscopy-guided-neonatal-intensive-care-management-for-the-nature 2024-11-07T11:20:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cerebral-near-infrared-spectroscopy-guided-neonatal-intensive-care-management-for-the-nature 2024-11-07T11:20:46+00:00 weekly 0.7 https://trial.medpath.com/news/using-abortion-pills-very-early-in-pregnancy-is-safe-study-finds 2024-11-07T11:08:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/using-abortion-pills-very-early-in-pregnancy-is-safe-study-finds 2024-11-07T11:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/psilocybin-shows-effectiveness-in-curbing-anorexia 2024-11-07T11:06:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psilocybin-shows-effectiveness-in-curbing-anorexia 2024-11-07T11:06:21+00:00 weekly 0.7 https://trial.medpath.com/news/new-wave-of-trials-in-huntington-s-disease-bring-hope-to-the-neurology-today 2024-11-07T11:00:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-wave-of-trials-in-huntington-s-disease-bring-hope-to-the-neurology-today 2024-11-07T11:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T10:46:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T10:46:04+00:00 weekly 0.7 https://trial.medpath.com/news/qutenza-r-phase-iii-clinical-trial-for-post-surgical-neuropathic-pain-successfully-enrolls 2024-11-07T10:31:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qutenza-r-phase-iii-clinical-trial-for-post-surgical-neuropathic-pain-successfully-enrolls 2024-11-07T10:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-regeneron-dupixent-approved-in-eu-for-young-children-with-eosinophilic-esophagitis 2024-11-07T10:26:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-regeneron-dupixent-approved-in-eu-for-young-children-with-eosinophilic-esophagitis 2024-11-07T10:26:35+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-design-for-phase-iii-trial-of-angelman-syndrome-therapy-yahoo-finance 2024-11-07T10:24:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-announces-design-for-phase-iii-trial-of-angelman-syndrome-therapy-yahoo-finance 2024-11-07T10:24:57+00:00 weekly 0.7 https://trial.medpath.com/news/cumberland-pharmaceuticals-receives-fda-orphan-drug-and-rare 2024-11-07T10:22:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cumberland-pharmaceuticals-receives-fda-orphan-drug-and-rare 2024-11-07T10:22:18+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-design-for-phase-iii-trial-of-angelman-syndrome-therapy 2024-11-07T10:21:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-announces-design-for-phase-iii-trial-of-angelman-syndrome-therapy 2024-11-07T10:21:34+00:00 weekly 0.7 https://trial.medpath.com/news/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T10:17:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T10:17:22+00:00 weekly 0.7 https://trial.medpath.com/news/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical-trial-with 2024-11-07T10:03:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical-trial-with 2024-11-07T10:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/inquis-raises-40m-for-pivotal-trial-of-clot-removal-device 2024-11-07T10:02:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inquis-raises-40m-for-pivotal-trial-of-clot-removal-device 2024-11-07T10:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T09:56:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T09:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-used-to-reduce-brain-damage-may-triple-death-risk-study-news18 2024-11-07T09:55:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-drug-used-to-reduce-brain-damage-may-triple-death-risk-study-news18 2024-11-07T09:55:34+00:00 weekly 0.7 https://trial.medpath.com/news/emergent-biosolutions-supports-new-clinical-trial-globenewswire 2024-11-07T09:51:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emergent-biosolutions-supports-new-clinical-trial-globenewswire 2024-11-07T09:51:10+00:00 weekly 0.7 https://trial.medpath.com/news/ema-approves-dupixent-for-young-eoe-patients-pharmaceutical-technology 2024-11-07T09:45:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-approves-dupixent-for-young-eoe-patients-pharmaceutical-technology 2024-11-07T09:45:19+00:00 weekly 0.7 https://trial.medpath.com/news/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T09:44:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T09:44:49+00:00 weekly 0.7 https://trial.medpath.com/news/maat-pharma-to-present-updates-from-early-access-program-at-the-2024-ash-annual 2024-11-07T09:44:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maat-pharma-to-present-updates-from-early-access-program-at-the-2024-ash-annual 2024-11-07T09:44:21+00:00 weekly 0.7 https://trial.medpath.com/news/oculis-reports-q3-2024-financial-results-and-provides-company-updates 2024-11-07T09:18:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oculis-reports-q3-2024-financial-results-and-provides-company-updates 2024-11-07T09:18:45+00:00 weekly 0.7 https://trial.medpath.com/news/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-for-patient-enrollment-in 2024-11-07T08:48:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-for-patient-enrollment-in 2024-11-07T08:48:18+00:00 weekly 0.7 https://trial.medpath.com/news/ema-approves-dupixent-to-treat-eosinophilic-esophagitis-in-children-as-young-as-one-year 2024-11-07T08:30:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-approves-dupixent-to-treat-eosinophilic-esophagitis-in-children-as-young-as-one-year 2024-11-07T08:30:10+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-trk-inhibitors-show-promise-in-treating-ntrk-fusion-positive-cancers 2024-11-07T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/next-generation-trk-inhibitors-show-promise-in-treating-ntrk-fusion-positive-cancers 2024-11-07T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-to-present-more-than-40-abstracts-across-nine-blood-disorders-at-the-66th-ash-meeting 2024-11-07T07:30:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-to-present-more-than-40-abstracts-across-nine-blood-disorders-at-the-66th-ash-meeting 2024-11-07T07:30:50+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-showcases-strength-of-haematology-portfolio-and-pipeline-at-ash-2024 2024-11-07T07:12:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-showcases-strength-of-haematology-portfolio-and-pipeline-at-ash-2024 2024-11-07T07:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/ultimovacs-asa-fra-7um-q3-2024-earnings-call-highlights-strat-gurufocus 2024-11-07T07:12:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultimovacs-asa-fra-7um-q3-2024-earnings-call-highlights-strat-gurufocus 2024-11-07T07:12:27+00:00 weekly 0.7 https://trial.medpath.com/news/uk-s-vpag-scheme-launches-new-metrics-framework-to-track-pharmaceutical-access-and-pricing 2024-11-07T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-s-vpag-scheme-launches-new-metrics-framework-to-track-pharmaceutical-access-and-pricing 2024-11-07T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/caris-life-sciences-receives-fda-approval-for-mi-cancer-seektm-as-a-companion 2024-11-07T06:43:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caris-life-sciences-receives-fda-approval-for-mi-cancer-seektm-as-a-companion 2024-11-07T06:43:21+00:00 weekly 0.7 https://trial.medpath.com/news/verastem-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-07T06:42:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verastem-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-07T06:42:56+00:00 weekly 0.7 https://trial.medpath.com/news/cellectar-to-present-new-phase-2-data-on-iopofosine-i-131-for-waldenstroms-macroglobulinemia-at-ash-2024 2024-11-07T06:40:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cellectar-to-present-new-phase-2-data-on-iopofosine-i-131-for-waldenstroms-macroglobulinemia-at-ash-2024 2024-11-07T06:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/doctors-in-australia-lead-phase-3-theranostics-study-targeting-advanced-prostate-cancer 2024-11-07T06:39:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/doctors-in-australia-lead-phase-3-theranostics-study-targeting-advanced-prostate-cancer 2024-11-07T06:39:39+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-phase-ii-trial-of-upar-pet-in-brain-cancer-patients-published-cision-news 2024-11-07T06:08:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-phase-ii-trial-of-upar-pet-in-brain-cancer-patients-published-cision-news 2024-11-07T06:08:25+00:00 weekly 0.7 https://trial.medpath.com/news/scope-of-things-scope-europe-2024-ai-in-clinical-trials-rising-stars-more 2024-11-07T06:00:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scope-of-things-scope-europe-2024-ai-in-clinical-trials-rising-stars-more 2024-11-07T06:00:01+00:00 weekly 0.7 https://trial.medpath.com/news/adopting-broader-clinical-trial-eligibility-in-lung-cancer-with-brain-mets-leptomeningeal-disease 2024-11-07T05:58:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adopting-broader-clinical-trial-eligibility-in-lung-cancer-with-brain-mets-leptomeningeal-disease 2024-11-07T05:58:18+00:00 weekly 0.7 https://trial.medpath.com/news/nccn-expands-genetic-testing-guidelines-to-include-prostate-cancer-and-updates-multi-cancer-risk-assessment 2024-11-07T05:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nccn-expands-genetic-testing-guidelines-to-include-prostate-cancer-and-updates-multi-cancer-risk-assessment 2024-11-07T05:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/advanced-hemophilia-treatments-show-promise-for-joint-health-while-access-barriers-persist-globally 2024-11-07T05:22:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advanced-hemophilia-treatments-show-promise-for-joint-health-while-access-barriers-persist-globally 2024-11-07T05:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-pharma-reports-q3-results-and-drug-progress-tipranks-com 2024-11-07T05:14:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urogen-pharma-reports-q3-results-and-drug-progress-tipranks-com 2024-11-07T05:14:35+00:00 weekly 0.7 https://trial.medpath.com/news/rna-editing-promises-to-go-where-dna-editing-can-t-the-hindu 2024-11-07T04:54:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rna-editing-promises-to-go-where-dna-editing-can-t-the-hindu 2024-11-07T04:54:59+00:00 weekly 0.7 https://trial.medpath.com/news/alcon-s-digital-transformation-success-clinical-trial-platform-drives-35-faster-database-delivery 2024-11-07T04:38:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alcon-s-digital-transformation-success-clinical-trial-platform-drives-35-faster-database-delivery 2024-11-07T04:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/case-study-suggests-some-men-with-advanced-prostate-cancer-could-benefit-from-t-dxd 2024-11-07T04:32:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/case-study-suggests-some-men-with-advanced-prostate-cancer-could-benefit-from-t-dxd 2024-11-07T04:32:05+00:00 weekly 0.7 https://trial.medpath.com/news/cyramza-tagrisso-combo-prolongs-pfs-in-some-patients-with-nsclc-subset-cure-today 2024-11-07T04:04:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cyramza-tagrisso-combo-prolongs-pfs-in-some-patients-with-nsclc-subset-cure-today 2024-11-07T04:04:23+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-drug-price-negotiations-face-uncertain-future-under-potential-trump-administration 2024-11-07T03:59:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicare-drug-price-negotiations-face-uncertain-future-under-potential-trump-administration 2024-11-07T03:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/askbio-receives-fda-rare-pediatric-disease-and-orphan-drug-designations-for-ab-1003-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2i-r9 2024-11-07T03:11:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/askbio-receives-fda-rare-pediatric-disease-and-orphan-drug-designations-for-ab-1003-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2i-r9 2024-11-07T03:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-botox-cosmetic-s-fda-approval-may-lead-to-higher-visibility-more-patient-inquiries 2024-11-07T03:09:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q-a-botox-cosmetic-s-fda-approval-may-lead-to-higher-visibility-more-patient-inquiries 2024-11-07T03:09:14+00:00 weekly 0.7 https://trial.medpath.com/news/grand-rounds-november-22-2024-tranexamic-acid-in-patients-undergoing-liver-resection 2024-11-07T02:45:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grand-rounds-november-22-2024-tranexamic-acid-in-patients-undergoing-liver-resection 2024-11-07T02:45:58+00:00 weekly 0.7 https://trial.medpath.com/news/radiotherapy-manchester-scientists-use-ai-to-simulate-cancer-patient-trials-bbc 2024-11-07T02:30:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiotherapy-manchester-scientists-use-ai-to-simulate-cancer-patient-trials-bbc 2024-11-07T02:30:20+00:00 weekly 0.7 https://trial.medpath.com/news/implementing-palliative-care-in-hepatocellular-carcinoma-ambulatory-clinics-study-protocol-trials 2024-11-07T02:30:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/implementing-palliative-care-in-hepatocellular-carcinoma-ambulatory-clinics-study-protocol-trials 2024-11-07T02:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-treated-in-new-phase-ii-clinical-trial-at-radiumhospitalet-in-oslo-cision-news 2024-11-07T01:38:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-treated-in-new-phase-ii-clinical-trial-at-radiumhospitalet-in-oslo-cision-news 2024-11-07T01:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-data-support-efficacy-safety-of-new-schizophrenia-drug-medpage-today 2024-11-07T01:25:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-data-support-efficacy-safety-of-new-schizophrenia-drug-medpage-today 2024-11-07T01:25:12+00:00 weekly 0.7 https://trial.medpath.com/news/seastar-medical-s-scd-wins-4th-fda-breakthrough-status-targets-48b-dialysis-market 2024-11-07T01:05:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/seastar-medical-s-scd-wins-4th-fda-breakthrough-status-targets-48b-dialysis-market 2024-11-07T01:05:10+00:00 weekly 0.7 https://trial.medpath.com/news/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2024 2024-11-07T01:03:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2024 2024-11-07T01:03:09+00:00 weekly 0.7 https://trial.medpath.com/news/soleno-therapeutics-inc-sec-10-q-report-tradingview 2024-11-07T00:41:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/soleno-therapeutics-inc-sec-10-q-report-tradingview 2024-11-07T00:41:31+00:00 weekly 0.7 https://trial.medpath.com/news/blackstone-s-proposed-acquisition-of-i-rom-raises-concerns-accc 2024-11-07T00:34:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blackstone-s-proposed-acquisition-of-i-rom-raises-concerns-accc 2024-11-07T00:34:44+00:00 weekly 0.7 https://trial.medpath.com/news/huidagene-therapeutics-crispr-cas13-rna-editing-therapy-hg202-gets-cgtlive-r 2024-11-07T00:21:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/huidagene-therapeutics-crispr-cas13-rna-editing-therapy-hg202-gets-cgtlive-r 2024-11-07T00:21:47+00:00 weekly 0.7 https://trial.medpath.com/news/jama-oncology-publishes-phase-1b-2-study-data-on-iaso-bio-s-equecabtagene-autoleucel-fucasotm-in-the-treatment-of-relapsed-refractory-multiple-myeloma 2024-11-07T00:11:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jama-oncology-publishes-phase-1b-2-study-data-on-iaso-bio-s-equecabtagene-autoleucel-fucasotm-in-the-treatment-of-relapsed-refractory-multiple-myeloma 2024-11-07T00:11:38+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-interview-with-president-and-ceo-frank-bedu-addo-about-the 2024-11-07T00:04:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotech-interview-with-president-and-ceo-frank-bedu-addo-about-the 2024-11-07T00:04:24+00:00 weekly 0.7 https://trial.medpath.com/news/north-texas-caris-life-sciences-gets-fda-approval-for-its-mi-cancer-seek-companion 2024-11-07T00:01:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/north-texas-caris-life-sciences-gets-fda-approval-for-its-mi-cancer-seek-companion 2024-11-07T00:01:06+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-drug-discovery-news 2024-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-drug-discovery-news 2024-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-biosciences-reports-third-quarter-2024-financial-results-and-highlights 2024-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tyra-biosciences-reports-third-quarter-2024-financial-results-and-highlights 2024-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-be 2024-11-06T23:54:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-be 2024-11-06T23:54:16+00:00 weekly 0.7 https://trial.medpath.com/news/elan-stock-report-elanco-animal-health-investors-are-globenewswire 2024-11-06T23:48:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elan-stock-report-elanco-animal-health-investors-are-globenewswire 2024-11-06T23:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/minghui-pharmaceutical-announces-promising-initial-results-from-phase-i-clinical-trial-biospace 2024-11-06T23:36:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minghui-pharmaceutical-announces-promising-initial-results-from-phase-i-clinical-trial-biospace 2024-11-06T23:36:09+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-s-shockwave-medical-shares-first-clinical-outcomes-associated-with 2024-11-06T23:20:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-s-shockwave-medical-shares-first-clinical-outcomes-associated-with 2024-11-06T23:20:46+00:00 weekly 0.7 https://trial.medpath.com/news/severe-asthma-clinical-trial-pipeline-appears-robust-with-40-key-pharma-companies 2024-11-06T22:45:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/severe-asthma-clinical-trial-pipeline-appears-robust-with-40-key-pharma-companies 2024-11-06T22:45:13+00:00 weekly 0.7 https://trial.medpath.com/news/sab-bio-announces-third-quarter-2024-financial-results-and-provides-company-update 2024-11-06T22:18:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sab-bio-announces-third-quarter-2024-financial-results-and-provides-company-update 2024-11-06T22:18:42+00:00 weekly 0.7 https://trial.medpath.com/news/brightspring-s-caremed-tapped-for-breakthrough-alzheimer-s-drug-leqembi-distribution 2024-11-06T22:12:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brightspring-s-caremed-tapped-for-breakthrough-alzheimer-s-drug-leqembi-distribution 2024-11-06T22:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-therapeutics-inc-sec-10-q-report-tradingview 2024-11-06T21:38:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarepta-therapeutics-inc-sec-10-q-report-tradingview 2024-11-06T21:38:57+00:00 weekly 0.7 https://trial.medpath.com/news/lytix-biopharma-first-patient-treated-in-new-phase-ii-clinical-trial-at-radiumhospitalet-in-oslo 2024-11-06T21:30:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lytix-biopharma-first-patient-treated-in-new-phase-ii-clinical-trial-at-radiumhospitalet-in-oslo 2024-11-06T21:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/arcutis-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-06T21:26:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arcutis-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-06T21:26:08+00:00 weekly 0.7 https://trial.medpath.com/news/vanda-pharmaceuticals-reports-third-quarter-2024-financial-results-morningstar 2024-11-06T21:20:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vanda-pharmaceuticals-reports-third-quarter-2024-financial-results-morningstar 2024-11-06T21:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/regenxbio-reports-third-quarter-2024-financial-results-and-recent-operational-updates 2024-11-06T21:20:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regenxbio-reports-third-quarter-2024-financial-results-and-recent-operational-updates 2024-11-06T21:20:35+00:00 weekly 0.7 https://trial.medpath.com/news/soleno-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-06T21:19:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/soleno-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-06T21:19:12+00:00 weekly 0.7 https://trial.medpath.com/news/nyxoah-reports-third-quarter-financial-and-operating-results-stock-titan 2024-11-06T21:15:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nyxoah-reports-third-quarter-financial-and-operating-results-stock-titan 2024-11-06T21:15:45+00:00 weekly 0.7 https://trial.medpath.com/news/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-for-patient-the-manila-times 2024-11-06T21:15:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-for-patient-the-manila-times 2024-11-06T21:15:43+00:00 weekly 0.7 https://trial.medpath.com/news/verastem-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-06T21:15:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verastem-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-06T21:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/adicet-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-06T21:15:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adicet-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-06T21:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/top-in-endocrinology-sotagliflozin-rejected-by-fda-new-lifestyle-intervention-guidelines 2024-11-06T21:14:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-in-endocrinology-sotagliflozin-rejected-by-fda-new-lifestyle-intervention-guidelines 2024-11-06T21:14:41+00:00 weekly 0.7 https://trial.medpath.com/news/aurobindo-obtains-fda-ok-for-generic-keflet-drug-store-news 2024-11-06T21:13:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aurobindo-obtains-fda-ok-for-generic-keflet-drug-store-news 2024-11-06T21:13:39+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-data-shows-lumateperone-delays-schizophrenia-relapse-longer-than-placebo 2024-11-06T21:01:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-data-shows-lumateperone-delays-schizophrenia-relapse-longer-than-placebo 2024-11-06T21:01:33+00:00 weekly 0.7 https://trial.medpath.com/news/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-globenewswire 2024-11-06T21:00:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-globenewswire 2024-11-06T21:00:45+00:00 weekly 0.7 https://trial.medpath.com/news/a-first-in-human-open-label-phase-ia-ib-multicenter-multiregional-dose-escalation-study 2024-11-06T21:00:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-first-in-human-open-label-phase-ia-ib-multicenter-multiregional-dose-escalation-study 2024-11-06T21:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-for-patient-enrollment-in 2024-11-06T20:58:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-for-patient-enrollment-in 2024-11-06T20:58:29+00:00 weekly 0.7 https://trial.medpath.com/news/corin-announces-fda-510-k-clearance-for-new-iconatm-femoral-stem-ortho-spine-news 2024-11-06T20:55:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corin-announces-fda-510-k-clearance-for-new-iconatm-femoral-stem-ortho-spine-news 2024-11-06T20:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-moderna-launch-phase-3-trial-for-mrna-4157-neoantigen-therapy-plus 2024-11-06T20:51:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-and-moderna-launch-phase-3-trial-for-mrna-4157-neoantigen-therapy-plus 2024-11-06T20:51:22+00:00 weekly 0.7 https://trial.medpath.com/news/japan-s-national-cancer-center-selects-paradigm-for-nationwide-clinical-trial-network 2024-11-06T20:37:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/japan-s-national-cancer-center-selects-paradigm-for-nationwide-clinical-trial-network 2024-11-06T20:37:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-withdrawal-of-trodelvy-leaves-fewer-bladder-cancer-options-cure-today 2024-11-06T20:19:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-withdrawal-of-trodelvy-leaves-fewer-bladder-cancer-options-cure-today 2024-11-06T20:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/around-the-helix-cell-and-gene-therapy-company-updates-november-6-2024 2024-11-06T20:12:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/around-the-helix-cell-and-gene-therapy-company-updates-november-6-2024 2024-11-06T20:12:25+00:00 weekly 0.7 https://trial.medpath.com/news/a-diabetes-drug-twice-rejected-stumbles-again-but-its-developer-persists-pharmavoice 2024-11-06T20:04:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-diabetes-drug-twice-rejected-stumbles-again-but-its-developer-persists-pharmavoice 2024-11-06T20:04:19+00:00 weekly 0.7 https://trial.medpath.com/news/platelet-counts-may-predict-long-term-ultomiris-response-in-ahus-study 2024-11-06T19:35:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/platelet-counts-may-predict-long-term-ultomiris-response-in-ahus-study 2024-11-06T19:35:58+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-s-alzheimer-s-drug-nears-p3-readout-but-sec-scandal-casts-long-shadow 2024-11-06T19:28:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cassava-s-alzheimer-s-drug-nears-p3-readout-but-sec-scandal-casts-long-shadow 2024-11-06T19:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/a-36-gene-predictive-score-of-anti-cancer-drug-resistance-anticipates-cancer-therapy-outcomes 2024-11-06T19:23:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-36-gene-predictive-score-of-anti-cancer-drug-resistance-anticipates-cancer-therapy-outcomes 2024-11-06T19:23:13+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-cellectis-reports-robust-cash-reserves-new-r-d-initiatives-investing-com 2024-11-06T19:18:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-cellectis-reports-robust-cash-reserves-new-r-d-initiatives-investing-com 2024-11-06T19:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/intra-cellular-bolsters-caplyta-data-with-another-phase-iii-win-pharmaceutical-technology 2024-11-06T19:09:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intra-cellular-bolsters-caplyta-data-with-another-phase-iii-win-pharmaceutical-technology 2024-11-06T19:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/nasal-swab-might-predict-how-severe-covid-will-be 2024-11-06T19:00:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nasal-swab-might-predict-how-severe-covid-will-be 2024-11-06T19:00:59+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-rhythm-pharmaceuticals-has-reported-a-successful-third-quarter-in-2024 2024-11-06T18:54:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-rhythm-pharmaceuticals-has-reported-a-successful-third-quarter-in-2024 2024-11-06T18:54:30+00:00 weekly 0.7 https://trial.medpath.com/news/study-to-assess-performance-of-cxbladder-test-in-urothelial-carcinoma-surveillance 2024-11-06T18:46:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-to-assess-performance-of-cxbladder-test-in-urothelial-carcinoma-surveillance 2024-11-06T18:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/ac102-shows-promise-as-treatment-for-sudden-hearing-loss 2024-11-06T18:43:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ac102-shows-promise-as-treatment-for-sudden-hearing-loss 2024-11-06T18:43:49+00:00 weekly 0.7 https://trial.medpath.com/news/canada-s-pharma-pipeline-expands-with-12000-new-medicines-as-oncology-leads-trials 2024-11-06T18:41:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/canada-s-pharma-pipeline-expands-with-12000-new-medicines-as-oncology-leads-trials 2024-11-06T18:41:30+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-ankyra-s-visceral-tumour-study-of-ank-101-clinical-trials-arena 2024-11-06T18:25:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-in-ankyra-s-visceral-tumour-study-of-ank-101-clinical-trials-arena 2024-11-06T18:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/milestone-as-pregnant-women-included-in-sa-tb-drug-trial-juta-medicalbrief 2024-11-06T18:20:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/milestone-as-pregnant-women-included-in-sa-tb-drug-trial-juta-medicalbrief 2024-11-06T18:20:12+00:00 weekly 0.7 https://trial.medpath.com/news/tetanus-clinical-trial-pipeline-insights-featuring-20-companies-delveinsight 2024-11-06T18:14:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tetanus-clinical-trial-pipeline-insights-featuring-20-companies-delveinsight 2024-11-06T18:14:57+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-s-qiastat-dx-meningitis-encephalitis-panel-gains-fda-clearance-for-rapid 2024-11-06T18:04:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qiagen-s-qiastat-dx-meningitis-encephalitis-panel-gains-fda-clearance-for-rapid 2024-11-06T18:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/sa-women-could-have-three-monthly-anti-hiv-ring-by-2026-juta-medicalbrief 2024-11-06T17:50:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sa-women-could-have-three-monthly-anti-hiv-ring-by-2026-juta-medicalbrief 2024-11-06T17:50:22+00:00 weekly 0.7 https://trial.medpath.com/news/national-institute-on-aging-invests-an-additional-7-3-million-into-nu-9-northwestern-now 2024-11-06T17:41:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/national-institute-on-aging-invests-an-additional-7-3-million-into-nu-9-northwestern-now 2024-11-06T17:41:18+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-approved-in-the-eu-as-the-first-and-only-medicine-for-young-children-with-pipelinereview 2024-11-06T17:40:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupixent-approved-in-the-eu-as-the-first-and-only-medicine-for-young-children-with-pipelinereview 2024-11-06T17:40:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-oral-drug-for-utis-despite-concerns-juta-medicalbrief 2024-11-06T17:40:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-oral-drug-for-utis-despite-concerns-juta-medicalbrief 2024-11-06T17:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-3-results-evaluating-lumateperone-for-the-prevention-of-relapse-in-schizophrenia 2024-11-06T17:17:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-phase-3-results-evaluating-lumateperone-for-the-prevention-of-relapse-in-schizophrenia 2024-11-06T17:17:29+00:00 weekly 0.7 https://trial.medpath.com/news/study-raises-hopes-of-treating-aggressive-cancers-by-zapping-rogue-dna-the-guardian 2024-11-06T17:15:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-raises-hopes-of-treating-aggressive-cancers-by-zapping-rogue-dna-the-guardian 2024-11-06T17:15:20+00:00 weekly 0.7 https://trial.medpath.com/news/the-value-of-a-negative-result-uc-davis-health 2024-11-06T17:12:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-value-of-a-negative-result-uc-davis-health 2024-11-06T17:12:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-phase-2-trial-of-leronlimab-for-microsatellite-stable-crc-targeted-oncology 2024-11-06T17:12:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-phase-2-trial-of-leronlimab-for-microsatellite-stable-crc-targeted-oncology 2024-11-06T17:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-pushes-pdufa-date-of-tapinarof-cream-1-for-atopic-dermatitis-to-2025 2024-11-06T17:11:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-pushes-pdufa-date-of-tapinarof-cream-1-for-atopic-dermatitis-to-2025 2024-11-06T17:11:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-bla-for-denosumab-biosimilar-hcplive 2024-11-06T17:11:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-bla-for-denosumab-biosimilar-hcplive 2024-11-06T17:11:15+00:00 weekly 0.7 https://trial.medpath.com/news/no-benefit-for-extended-lymph-node-surgery-in-mibc-national-cancer-institute 2024-11-06T17:08:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/no-benefit-for-extended-lymph-node-surgery-in-mibc-national-cancer-institute 2024-11-06T17:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/domvanalimab-combo-improves-survival-in-advanced-metastatic-nsclc-cancer-network 2024-11-06T17:07:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/domvanalimab-combo-improves-survival-in-advanced-metastatic-nsclc-cancer-network 2024-11-06T17:07:29+00:00 weekly 0.7 https://trial.medpath.com/news/reviva-to-present-positive-speech-latency-data-for-brilaroxazine-in-schizophrenia-from-the 2024-11-06T17:03:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reviva-to-present-positive-speech-latency-data-for-brilaroxazine-in-schizophrenia-from-the 2024-11-06T17:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-gets-us-fda-nod-to-begin-phase-ii-oncology-trial-of-leronlimab-in-patients-with-r-r 2024-11-06T17:00:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytodyn-gets-us-fda-nod-to-begin-phase-ii-oncology-trial-of-leronlimab-in-patients-with-r-r 2024-11-06T17:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-lbl-034-for-multiple-myeloma-onclive 2024-11-06T16:49:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-lbl-034-for-multiple-myeloma-onclive 2024-11-06T16:49:18+00:00 weekly 0.7 https://trial.medpath.com/news/mi-cancer-seek-receives-fda-approval-as-companion-diagnostic-for-targeted-therapy 2024-11-06T16:49:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mi-cancer-seek-receives-fda-approval-as-companion-diagnostic-for-targeted-therapy 2024-11-06T16:49:04+00:00 weekly 0.7 https://trial.medpath.com/news/caris-life-sciences-nabs-fda-approval-for-multicancer-companion-diagnostic 2024-11-06T16:48:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caris-life-sciences-nabs-fda-approval-for-multicancer-companion-diagnostic 2024-11-06T16:48:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-market-authorization-to-light-therapy-system-for-dry-amd-medpage-today 2024-11-06T16:40:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-market-authorization-to-light-therapy-system-for-dry-amd-medpage-today 2024-11-06T16:40:45+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-said-to-shuffle-sales-leadership-vertex-records-first-casgevy-sale 2024-11-06T16:38:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-said-to-shuffle-sales-leadership-vertex-records-first-casgevy-sale 2024-11-06T16:38:32+00:00 weekly 0.7 https://trial.medpath.com/news/fidanacogene-elaparvovec-shows-strong-results-in-open-label-phase-3-study 2024-11-06T16:29:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fidanacogene-elaparvovec-shows-strong-results-in-open-label-phase-3-study 2024-11-06T16:29:56+00:00 weekly 0.7 https://trial.medpath.com/news/lumithera-s-valeda-light-delivery-system-receives-marketing-authorization-from-fda 2024-11-06T16:26:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lumithera-s-valeda-light-delivery-system-receives-marketing-authorization-from-fda 2024-11-06T16:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/caris-life-sciences-nabs-fda-approval-for-multicancer-companion-diagnostic 2024-11-06T16:19:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caris-life-sciences-nabs-fda-approval-for-multicancer-companion-diagnostic 2024-11-06T16:19:04+00:00 weekly 0.7 https://trial.medpath.com/news/fda-renews-approval-for-jaguar-s-cid-treatment-in-dogs-investing-com 2024-11-06T16:16:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-renews-approval-for-jaguar-s-cid-treatment-in-dogs-investing-com 2024-11-06T16:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-pharma-reports-2024-third-quarter-financial-results-and-business-highlights 2024-11-06T16:14:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urogen-pharma-reports-2024-third-quarter-financial-results-and-business-highlights 2024-11-06T16:14:36+00:00 weekly 0.7 https://trial.medpath.com/news/once-weekly-semaglutide-reduces-knee-osteoarthritis-pain-body-weight-in-patients-with 2024-11-06T16:13:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/once-weekly-semaglutide-reduces-knee-osteoarthritis-pain-body-weight-in-patients-with 2024-11-06T16:13:45+00:00 weekly 0.7 https://trial.medpath.com/news/t-cell-lymphoma-pipeline-insight-analysis-report-2024-globenewswire 2024-11-06T16:03:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t-cell-lymphoma-pipeline-insight-analysis-report-2024-globenewswire 2024-11-06T16:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/cracking-the-code-of-dna-circles-in-cancer-stanford-medicine-led-team-uncovers-potential-therapy 2024-11-06T16:01:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cracking-the-code-of-dna-circles-in-cancer-stanford-medicine-led-team-uncovers-potential-therapy 2024-11-06T16:01:24+00:00 weekly 0.7 https://trial.medpath.com/news/senhwa-biosciences-announces-first-patient-dosed-in-the-phase-i-ii-study-of-silmitasertib-in 2024-11-06T15:56:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senhwa-biosciences-announces-first-patient-dosed-in-the-phase-i-ii-study-of-silmitasertib-in 2024-11-06T15:56:38+00:00 weekly 0.7 https://trial.medpath.com/news/inhibiting-viral-rna-cap-methylation-with-anti-viral-molecules-news-medical 2024-11-06T15:53:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inhibiting-viral-rna-cap-methylation-with-anti-viral-molecules-news-medical 2024-11-06T15:53:58+00:00 weekly 0.7 https://trial.medpath.com/news/senhwa-biosciences-announces-first-patient-dosed-in-the-phase-i-ii-study-of-silmitasertib-in 2024-11-06T15:43:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senhwa-biosciences-announces-first-patient-dosed-in-the-phase-i-ii-study-of-silmitasertib-in 2024-11-06T15:43:23+00:00 weekly 0.7 https://trial.medpath.com/news/precision-medicine-in-sclc-key-biomarkers-revealed-mirage-news 2024-11-06T15:38:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-medicine-in-sclc-key-biomarkers-revealed-mirage-news 2024-11-06T15:38:52+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-atezolizumab-plus-bevacizumab-to-chemotherapy-in-advanced-biliary-tract-cancer 2024-11-06T15:33:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-atezolizumab-plus-bevacizumab-to-chemotherapy-in-advanced-biliary-tract-cancer 2024-11-06T15:33:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-renewal-of-canalevia-ca1-jaguar-health-s-drug-for-chemotherapy-stock-titan 2024-11-06T15:31:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-renewal-of-canalevia-ca1-jaguar-health-s-drug-for-chemotherapy-stock-titan 2024-11-06T15:31:21+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-to-present-new-analytical-results-at-diabetes-congress-marketscreener 2024-11-06T15:27:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-to-present-new-analytical-results-at-diabetes-congress-marketscreener 2024-11-06T15:27:32+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-oral-serd-in-postmenopausal-women-with-er-positive-her2-negative 2024-11-06T15:13:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/next-generation-oral-serd-in-postmenopausal-women-with-er-positive-her2-negative 2024-11-06T15:13:55+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-to-acquire-longboard-drug-store-news 2024-11-06T15:13:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lundbeck-to-acquire-longboard-drug-store-news 2024-11-06T15:13:36+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-doses-first-subject-in-phase-i-trial-of-zw191-for-solid-tumours 2024-11-06T15:11:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zymeworks-doses-first-subject-in-phase-i-trial-of-zw191-for-solid-tumours 2024-11-06T15:11:47+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-advances-patient-dosing-to-final-stages-in-phase-ii-trial-for-acute 2024-11-06T15:04:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-advances-patient-dosing-to-final-stages-in-phase-ii-trial-for-acute 2024-11-06T15:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/dementia-combo-of-2-active-therapies-may-slow-cognitive-decline 2024-11-06T14:51:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dementia-combo-of-2-active-therapies-may-slow-cognitive-decline 2024-11-06T14:51:21+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-advances-patient-dosing-to-final-stages-in-phase-ii-trial-for-acute 2024-11-06T14:44:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-advances-patient-dosing-to-final-stages-in-phase-ii-trial-for-acute 2024-11-06T14:44:31+00:00 weekly 0.7 https://trial.medpath.com/news/startup-gives-surgeons-a-real-time-view-of-breast-cancer-during-surgery-mit-news 2024-11-06T14:39:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/startup-gives-surgeons-a-real-time-view-of-breast-cancer-during-surgery-mit-news 2024-11-06T14:39:15+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-status-to-seastar-medical-s-scd-investing-com 2024-11-06T14:18:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-status-to-seastar-medical-s-scd-investing-com 2024-11-06T14:18:09+00:00 weekly 0.7 https://trial.medpath.com/news/first-of-a-kind-eu-approval-granted-for-eosinophilic-esophagitis-medicine 2024-11-06T14:17:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-of-a-kind-eu-approval-granted-for-eosinophilic-esophagitis-medicine 2024-11-06T14:17:34+00:00 weekly 0.7 https://trial.medpath.com/news/patient-dies-in-beam-trial-of-scd-candidate-company-cites-conditioning 2024-11-06T14:12:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-dies-in-beam-trial-of-scd-candidate-company-cites-conditioning 2024-11-06T14:12:18+00:00 weekly 0.7 https://trial.medpath.com/news/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-pr-newswire 2024-11-06T14:11:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-pr-newswire 2024-11-06T14:11:43+00:00 weekly 0.7 https://trial.medpath.com/news/intra-cellular-bolsters-caplyta-data-with-another-phase-iii-win-clinical-trials-arena 2024-11-06T14:10:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intra-cellular-bolsters-caplyta-data-with-another-phase-iii-win-clinical-trials-arena 2024-11-06T14:10:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-for-seastar-globenewswire 2024-11-06T14:04:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-for-seastar-globenewswire 2024-11-06T14:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/zollinger-ellison-syndrome-gastrinoma-global-clinical-trials-review-2024-yahoo-finance 2024-11-06T14:03:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zollinger-ellison-syndrome-gastrinoma-global-clinical-trials-review-2024-yahoo-finance 2024-11-06T14:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/zollinger-ellison-syndrome-gastrinoma-global-clinical-globenewswire 2024-11-06T13:58:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zollinger-ellison-syndrome-gastrinoma-global-clinical-globenewswire 2024-11-06T13:58:38+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-reports-third-quarter-2024-financial-results-company-announcement-ft-com 2024-11-06T13:49:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-reports-third-quarter-2024-financial-results-company-announcement-ft-com 2024-11-06T13:49:54+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-firms-showcase-innovative-treatment-for-major-diseases-at-ciie-shine-news 2024-11-06T13:49:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-firms-showcase-innovative-treatment-for-major-diseases-at-ciie-shine-news 2024-11-06T13:49:44+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-pharma-reports-2024-third-quarter-financial-results-and-business-highlights 2024-11-06T13:40:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urogen-pharma-reports-2024-third-quarter-financial-results-and-business-highlights 2024-11-06T13:40:50+00:00 weekly 0.7 https://trial.medpath.com/news/promising-use-of-lytix-cancer-treatment-in-patients-with-early-stage-melanoma-finansavisen 2024-11-06T13:23:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-use-of-lytix-cancer-treatment-in-patients-with-early-stage-melanoma-finansavisen 2024-11-06T13:23:24+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-advances-patient-dosing-to-final-globenewswire 2024-11-06T13:23:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-advances-patient-dosing-to-final-globenewswire 2024-11-06T13:23:20+00:00 weekly 0.7 https://trial.medpath.com/news/leal-raises-45m-to-advance-ltx-002-to-clinical-trials-for-als-als-news-today 2024-11-06T13:17:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leal-raises-45m-to-advance-ltx-002-to-clinical-trials-for-als-als-news-today 2024-11-06T13:17:51+00:00 weekly 0.7 https://trial.medpath.com/news/reviva-to-present-positive-speech-latency-data-for-globenewswire 2024-11-06T13:17:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reviva-to-present-positive-speech-latency-data-for-globenewswire 2024-11-06T13:17:08+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-to-announce-third-quarter-financial-results-on-globenewswire 2024-11-06T13:17:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotech-to-announce-third-quarter-financial-results-on-globenewswire 2024-11-06T13:17:04+00:00 weekly 0.7 https://trial.medpath.com/news/uniqure-announces-third-quarter-2024-financial-results-and-highlights-recent-company-progress 2024-11-06T13:15:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uniqure-announces-third-quarter-2024-financial-results-and-highlights-recent-company-progress 2024-11-06T13:15:41+00:00 weekly 0.7 https://trial.medpath.com/news/reviva-pharma-to-present-breakthrough-phase-3-schizophrenia-drug-data-at-cns-summit 2024-11-06T13:14:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reviva-pharma-to-present-breakthrough-phase-3-schizophrenia-drug-data-at-cns-summit 2024-11-06T13:14:24+00:00 weekly 0.7 https://trial.medpath.com/news/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T13:13:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T13:13:47+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-06T13:07:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-06T13:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-lugano-trial-explores-eyp-1901-s-potential-to-reduce-treatment-burden-in-wet 2024-11-06T13:06:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-lugano-trial-explores-eyp-1901-s-potential-to-reduce-treatment-burden-in-wet 2024-11-06T13:06:58+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-reports-third-quarter-2024-financial-results-news-cnhinews-com 2024-11-06T13:04:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-reports-third-quarter-2024-financial-results-news-cnhinews-com 2024-11-06T13:04:07+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-data-shows-tev-749-injection-improves-social-function-in-schizophrenia 2024-11-06T13:01:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-data-shows-tev-749-injection-improves-social-function-in-schizophrenia 2024-11-06T13:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/glycomimetics-announces-new-uproleselan-clinical-data-will-be-presented-at-ash-annual-meeting 2024-11-06T13:00:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glycomimetics-announces-new-uproleselan-clinical-data-will-be-presented-at-ash-annual-meeting 2024-11-06T13:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-pivotal-phase-3-trial-design-for-ion582-in-angelman-syndrome 2024-11-06T13:00:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-announces-pivotal-phase-3-trial-design-for-ion582-in-angelman-syndrome 2024-11-06T13:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-treated-in-new-phase-ii-clinical-trial-at-radiumhospitalet-in-oslo-tradingview 2024-11-06T12:56:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-treated-in-new-phase-ii-clinical-trial-at-radiumhospitalet-in-oslo-tradingview 2024-11-06T12:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2024 2024-11-06T12:53:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2024 2024-11-06T12:53:24+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-s-balversa-granted-mhra-approval-in-bladder-cancer-pmlive 2024-11-06T12:41:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-s-balversa-granted-mhra-approval-in-bladder-cancer-pmlive 2024-11-06T12:41:10+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-journey-medical-s-emrosi-to-treat-inflammatory-lesions-of-rosacea-pmlive 2024-11-06T12:40:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-journey-medical-s-emrosi-to-treat-inflammatory-lesions-of-rosacea-pmlive 2024-11-06T12:40:48+00:00 weekly 0.7 https://trial.medpath.com/news/elevation-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-06T12:36:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elevation-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-06T12:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/update-to-the-statistical-analysis-plan-for-notacs-a-multicentre-adaptive-randomised-controlled-trial 2024-11-06T12:36:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/update-to-the-statistical-analysis-plan-for-notacs-a-multicentre-adaptive-randomised-controlled-trial 2024-11-06T12:36:17+00:00 weekly 0.7 https://trial.medpath.com/news/elevation-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-06T12:35:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elevation-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-06T12:35:44+00:00 weekly 0.7 https://trial.medpath.com/news/praxis-precision-medicines-provides-corporate-update-and-globenewswire 2024-11-06T12:34:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/praxis-precision-medicines-provides-corporate-update-and-globenewswire 2024-11-06T12:34:12+00:00 weekly 0.7 https://trial.medpath.com/news/caris-life-sciences-receives-fda-approval-for-mi-cancer-seektm-as-a-companion 2024-11-06T12:33:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caris-life-sciences-receives-fda-approval-for-mi-cancer-seektm-as-a-companion 2024-11-06T12:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-reports-third-quarter-2024-financial-results-morningstar 2024-11-06T12:32:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-reports-third-quarter-2024-financial-results-morningstar 2024-11-06T12:32:59+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-reports-third-quarter-2024-financial-results-stock-titan 2024-11-06T12:19:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-reports-third-quarter-2024-financial-results-stock-titan 2024-11-06T12:19:06+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-r-dupilumab-approved-in-the-european-union-as-the-first-and-only-medicine-for 2024-11-06T12:13:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupixent-r-dupilumab-approved-in-the-european-union-as-the-first-and-only-medicine-for 2024-11-06T12:13:38+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-reports-third-quarter-2024-financial-results-placera 2024-11-06T12:10:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-reports-third-quarter-2024-financial-results-placera 2024-11-06T12:10:07+00:00 weekly 0.7 https://trial.medpath.com/news/insignis-therapeutics-in-001-clinical-programme-receives-positive-fda-response 2024-11-06T12:08:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insignis-therapeutics-in-001-clinical-programme-receives-positive-fda-response 2024-11-06T12:08:59+00:00 weekly 0.7 https://trial.medpath.com/news/lenz-therapeutics-reports-third-quarter-2024-financial-results-morningstar 2024-11-06T12:08:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenz-therapeutics-reports-third-quarter-2024-financial-results-morningstar 2024-11-06T12:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-herbal-medicine-may-aid-dementia-prevention-mirage-news 2024-11-06T12:05:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chinese-herbal-medicine-may-aid-dementia-prevention-mirage-news 2024-11-06T12:05:15+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-pivotal-phase-3-trial-design-for-ion582-in-angelman-syndrome 2024-11-06T12:04:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-announces-pivotal-phase-3-trial-design-for-ion582-in-angelman-syndrome 2024-11-06T12:04:14+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-reports-third-quarter-2024-financial-results-pr-newswire 2024-11-06T12:04:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-reports-third-quarter-2024-financial-results-pr-newswire 2024-11-06T12:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/imugene-bile-cancer-patient-maintains-full-response-mirage-news 2024-11-06T11:43:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imugene-bile-cancer-patient-maintains-full-response-mirage-news 2024-11-06T11:43:54+00:00 weekly 0.7 https://trial.medpath.com/news/caris-life-sciences-receives-fda-approval-for-mi-cancer-seektm-as-a-companion 2024-11-06T11:36:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caris-life-sciences-receives-fda-approval-for-mi-cancer-seektm-as-a-companion 2024-11-06T11:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-grants-approval-for-bladder-cancer-drug-erdafitinib-pharmatimes 2024-11-06T11:08:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mhra-grants-approval-for-bladder-cancer-drug-erdafitinib-pharmatimes 2024-11-06T11:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/italy-tests-first-gene-edited-vines-for-winemaking-nature-biotechnology 2024-11-06T11:07:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/italy-tests-first-gene-edited-vines-for-winemaking-nature-biotechnology 2024-11-06T11:07:30+00:00 weekly 0.7 https://trial.medpath.com/news/new-trial-seeks-to-improve-ewing-sarcoma-treatment-outcomes-technology-networks 2024-11-06T11:02:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-trial-seeks-to-improve-ewing-sarcoma-treatment-outcomes-technology-networks 2024-11-06T11:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/gender-gap-persists-in-hematology-oncology-leadership-despite-growing-female-representation-in-medicine 2024-11-06T11:00:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gender-gap-persists-in-hematology-oncology-leadership-despite-growing-female-representation-in-medicine 2024-11-06T11:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-signs-deal-for-monthly-glp-1-agonist-european-biotechnology-magazine 2024-11-06T10:42:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-signs-deal-for-monthly-glp-1-agonist-european-biotechnology-magazine 2024-11-06T10:42:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-first-crispr-cas13-rna-editing-trial-for-macular-degeneration 2024-11-06T10:39:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-first-crispr-cas13-rna-editing-trial-for-macular-degeneration 2024-11-06T10:39:08+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-approved-in-the-eu-as-the-first-and-only-medicine-for-young 2024-11-06T10:30:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-dupixent-approved-in-the-eu-as-the-first-and-only-medicine-for-young 2024-11-06T10:30:13+00:00 weekly 0.7 https://trial.medpath.com/news/capsida-biotherapeutics-cap-003-displays-properties-of-disease-modification-in-cgtlive-r 2024-11-06T10:17:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/capsida-biotherapeutics-cap-003-displays-properties-of-disease-modification-in-cgtlive-r 2024-11-06T10:17:18+00:00 weekly 0.7 https://trial.medpath.com/news/lumateperone-demonstrates-efficacy-in-reducing-symptomatic-relapse-risk-in-schizophrenia 2024-11-06T10:16:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lumateperone-demonstrates-efficacy-in-reducing-symptomatic-relapse-risk-in-schizophrenia 2024-11-06T10:16:39+00:00 weekly 0.7 https://trial.medpath.com/news/minghui-pharmaceutical-announces-promising-initial-results-from-phase-i-clinical-trial-of 2024-11-06T10:04:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minghui-pharmaceutical-announces-promising-initial-results-from-phase-i-clinical-trial-of 2024-11-06T10:04:14+00:00 weekly 0.7 https://trial.medpath.com/news/eu-s-new-wastewater-treatment-directive-raises-concerns-over-generic-medicine-access 2024-11-06T10:03:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-s-new-wastewater-treatment-directive-raises-concerns-over-generic-medicine-access 2024-11-06T10:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/insignis-therapeutics-receives-positive-fda-feedback-on-in-001-clinical-program-for 2024-11-06T09:14:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insignis-therapeutics-receives-positive-fda-feedback-on-in-001-clinical-program-for 2024-11-06T09:14:59+00:00 weekly 0.7 https://trial.medpath.com/news/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T09:14:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T09:14:58+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-06T09:14:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-06T09:14:57+00:00 weekly 0.7 https://trial.medpath.com/news/lyell-announces-presentation-of-initial-clinical-data-from-the-phase-1-2-clinical-trial-of-biospace 2024-11-06T09:14:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lyell-announces-presentation-of-initial-clinical-data-from-the-phase-1-2-clinical-trial-of-biospace 2024-11-06T09:14:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-roundup-november-5-2024-biospace 2024-11-06T09:14:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-roundup-november-5-2024-biospace 2024-11-06T09:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-biospace 2024-11-06T09:14:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-biospace 2024-11-06T09:14:52+00:00 weekly 0.7 https://trial.medpath.com/news/update-on-fda-review-of-vtama-r-tapinarof-cream-1-for-the-treatment-of-atopic-biospace 2024-11-06T09:14:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/update-on-fda-review-of-vtama-r-tapinarof-cream-1-for-the-treatment-of-atopic-biospace 2024-11-06T09:14:51+00:00 weekly 0.7 https://trial.medpath.com/news/protagonist-therapeutics-announces-poster-presentation-on-final-revive-phase-2-study 2024-11-06T09:14:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protagonist-therapeutics-announces-poster-presentation-on-final-revive-phase-2-study 2024-11-06T09:14:48+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-rsv-vaccine-approved-in-canada-for-adults-aged-50-to-59 2024-11-06T09:05:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-s-rsv-vaccine-approved-in-canada-for-adults-aged-50-to-59 2024-11-06T09:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/vesper-bio-announces-successful-completion-of-phase-1-clinical-trial-for-ftd-grn-treatment 2024-11-06T09:00:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vesper-bio-announces-successful-completion-of-phase-1-clinical-trial-for-ftd-grn-treatment 2024-11-06T09:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/jlk-receives-fda-approval-for-its-ai-stroke-diagnosis-solution-jlk-pwi-businesskorea 2024-11-06T08:55:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jlk-receives-fda-approval-for-its-ai-stroke-diagnosis-solution-jlk-pwi-businesskorea 2024-11-06T08:55:54+00:00 weekly 0.7 https://trial.medpath.com/news/dr-lotan-on-ongoing-research-with-novel-agents-in-bcg-unresponsive-nmibc-onclive 2024-11-06T08:47:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-lotan-on-ongoing-research-with-novel-agents-in-bcg-unresponsive-nmibc-onclive 2024-11-06T08:47:10+00:00 weekly 0.7 https://trial.medpath.com/news/ruxolitinib-plus-pegylated-interferon-alfa-2a-is-safe-and-effective-in-in-newly-diagnosed-pv 2024-11-06T08:46:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ruxolitinib-plus-pegylated-interferon-alfa-2a-is-safe-and-effective-in-in-newly-diagnosed-pv 2024-11-06T08:46:45+00:00 weekly 0.7 https://trial.medpath.com/news/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-morningstar 2024-11-06T08:36:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-morningstar 2024-11-06T08:36:19+00:00 weekly 0.7 https://trial.medpath.com/news/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-be 2024-11-06T08:13:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-be 2024-11-06T08:13:26+00:00 weekly 0.7 https://trial.medpath.com/news/noninflammatory-neurotoxicity-events-in-patients-receiving-car-t-cgtlive-r 2024-11-06T07:06:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/noninflammatory-neurotoxicity-events-in-patients-receiving-car-t-cgtlive-r 2024-11-06T07:06:55+00:00 weekly 0.7 https://trial.medpath.com/news/patient-death-reported-in-beam-scd-phase-i-ii-study-bioworld 2024-11-06T06:51:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-death-reported-in-beam-scd-phase-i-ii-study-bioworld 2024-11-06T06:51:11+00:00 weekly 0.7 https://trial.medpath.com/news/igi-reports-75-response-rate-in-multiple-myeloma-drug-trial-the-hindu-businessline 2024-11-06T06:47:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/igi-reports-75-response-rate-in-multiple-myeloma-drug-trial-the-hindu-businessline 2024-11-06T06:47:16+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-r-dupilumab-approved-in-the-european-union-as-the-first-and-only-medicine-for 2024-11-06T06:45:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupixent-r-dupilumab-approved-in-the-european-union-as-the-first-and-only-medicine-for 2024-11-06T06:45:14+00:00 weekly 0.7 https://trial.medpath.com/news/ultimovacs-asa-reports-third-quarter-2024-financial-results-globenewswire 2024-11-06T06:43:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultimovacs-asa-reports-third-quarter-2024-financial-results-globenewswire 2024-11-06T06:43:29+00:00 weekly 0.7 https://trial.medpath.com/news/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T06:34:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T06:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/korean-aml-drug-shows-50-overall-complete-response-rate-in-p1-trial-kbr 2024-11-06T06:28:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/korean-aml-drug-shows-50-overall-complete-response-rate-in-p1-trial-kbr 2024-11-06T06:28:08+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-approved-in-the-eu-as-the-first-and-globenewswire 2024-11-06T06:09:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-dupixent-approved-in-the-eu-as-the-first-and-globenewswire 2024-11-06T06:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/final-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-pr-newswire 2024-11-06T05:58:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/final-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-pr-newswire 2024-11-06T05:58:47+00:00 weekly 0.7 https://trial.medpath.com/news/final-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-yahoo-finance 2024-11-06T05:25:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/final-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-yahoo-finance 2024-11-06T05:25:22+00:00 weekly 0.7 https://trial.medpath.com/news/rosacea-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-06T04:43:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rosacea-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-06T04:43:07+00:00 weekly 0.7 https://trial.medpath.com/news/bostongene-advances-precision-oncology-with-ai-driven-molecular-profiling-research-at-major-cancer-symposiums 2024-11-06T04:34:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bostongene-advances-precision-oncology-with-ai-driven-molecular-profiling-research-at-major-cancer-symposiums 2024-11-06T04:34:35+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-highlights-clinical-data-to-be-presented-at-the-globenewswire 2024-11-06T04:09:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hutchmed-highlights-clinical-data-to-be-presented-at-the-globenewswire 2024-11-06T04:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/cstone-pharmaceuticals-to-unveil-promising-lymphoma-drug-data-markets-insider 2024-11-06T03:55:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cstone-pharmaceuticals-to-unveil-promising-lymphoma-drug-data-markets-insider 2024-11-06T03:55:37+00:00 weekly 0.7 https://trial.medpath.com/news/acadia-pharmaceuticals-secures-150m-in-priority-review-voucher-sale-setting-high-benchmark 2024-11-06T03:35:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-secures-150m-in-priority-review-voucher-sale-setting-high-benchmark 2024-11-06T03:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-to-help-patients-undergoing-cancer-immunotherapy-yale-school-of-medicine 2024-11-06T03:24:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-to-help-patients-undergoing-cancer-immunotherapy-yale-school-of-medicine 2024-11-06T03:24:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-pushes-back-pdufa-date-3-months-for-tapinarof-1-cream-for-atopic-dermatitis-in 2024-11-06T02:54:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-pushes-back-pdufa-date-3-months-for-tapinarof-1-cream-for-atopic-dermatitis-in 2024-11-06T02:54:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-delays-decision-on-merus-bispecific-antibody-to-review-cmc-information-biospace 2024-11-06T02:36:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-delays-decision-on-merus-bispecific-antibody-to-review-cmc-information-biospace 2024-11-06T02:36:10+00:00 weekly 0.7 https://trial.medpath.com/news/research-grid-secures-6-5m-seed-funding-to-revolutionize-clinical-trial-efficiency-with-ai 2024-11-06T01:52:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-grid-secures-6-5m-seed-funding-to-revolutionize-clinical-trial-efficiency-with-ai 2024-11-06T01:52:11+00:00 weekly 0.7 https://trial.medpath.com/news/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T00:50:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T00:50:11+00:00 weekly 0.7 https://trial.medpath.com/news/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T00:33:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T00:33:11+00:00 weekly 0.7 https://trial.medpath.com/news/nanoscope-therapeutics-retinitis-pigmentosa-gene-therapy-mco-010-improves-visual 2024-11-06T00:16:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoscope-therapeutics-retinitis-pigmentosa-gene-therapy-mco-010-improves-visual 2024-11-06T00:16:57+00:00 weekly 0.7 https://trial.medpath.com/news/leads-biolabs-receives-orphan-drug-designation-from-the-us-fda-for-lbl-034-a-uniquely-designed-highly-differentiated-anti-gprc5d-cd3-bispecific-antibody-for-the-treatment-of-multiple-myeloma 2024-11-06T00:11:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leads-biolabs-receives-orphan-drug-designation-from-the-us-fda-for-lbl-034-a-uniquely-designed-highly-differentiated-anti-gprc5d-cd3-bispecific-antibody-for-the-treatment-of-multiple-myeloma 2024-11-06T00:11:07+00:00 weekly 0.7 https://trial.medpath.com/news/how-hypoxia-helps-cancer-spread-johns-hopkins-medicine 2024-11-06T00:01:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-hypoxia-helps-cancer-spread-johns-hopkins-medicine 2024-11-06T00:01:53+00:00 weekly 0.7 https://trial.medpath.com/news/pp-007-receives-fda-fast-track-designation-for-treatment-of-acute-ischemic-stroke 2024-11-05T23:59:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pp-007-receives-fda-fast-track-designation-for-treatment-of-acute-ischemic-stroke 2024-11-05T23:59:12+00:00 weekly 0.7 https://trial.medpath.com/news/implementation-of-the-new-european-health-technology-assessment-regulation-htar 2024-11-05T23:57:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/implementation-of-the-new-european-health-technology-assessment-regulation-htar 2024-11-05T23:57:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-journey-s-rosacea-drug-eu-to-decide-on-novo-s-catalent-acquisition-by-6-december 2024-11-05T23:44:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-journey-s-rosacea-drug-eu-to-decide-on-novo-s-catalent-acquisition-by-6-december 2024-11-05T23:44:31+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-launches-phase-ii-trial-of-alisertib-for-hr-positive-metastatic-breast-cancer 2024-11-05T23:01:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotechnology-launches-phase-ii-trial-of-alisertib-for-hr-positive-metastatic-breast-cancer 2024-11-05T23:01:52+00:00 weekly 0.7 https://trial.medpath.com/news/new-swiss-clinical-trial-framework-takes-effect-with-updated-reporting-rules-citeline 2024-11-05T22:59:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-swiss-clinical-trial-framework-takes-effect-with-updated-reporting-rules-citeline 2024-11-05T22:59:56+00:00 weekly 0.7 https://trial.medpath.com/news/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-product-in-pediatric-netherton 2024-11-05T22:06:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-product-in-pediatric-netherton 2024-11-05T22:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/anaptysbio-inc-sec-10-q-report-tradingview 2024-11-05T22:03:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anaptysbio-inc-sec-10-q-report-tradingview 2024-11-05T22:03:58+00:00 weekly 0.7 https://trial.medpath.com/news/stoke-therapeutics-inc-sec-10-q-report-tradingview 2024-11-05T22:03:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stoke-therapeutics-inc-sec-10-q-report-tradingview 2024-11-05T22:03:58+00:00 weekly 0.7 https://trial.medpath.com/news/an-orally-bioavailable-gcn2-kinase-activator-for-the-treatment-of-clear-cell-renal-cell-carcinoma-and-acute-myeloid-leukemia 2024-11-05T21:53:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-orally-bioavailable-gcn2-kinase-activator-for-the-treatment-of-clear-cell-renal-cell-carcinoma-and-acute-myeloid-leukemia 2024-11-05T21:53:39+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-combo-shows-significant-promise-in-advanced-melanoma-trial 2024-11-05T21:41:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-combo-shows-significant-promise-in-advanced-melanoma-trial 2024-11-05T21:41:47+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-s-atev-promising-clinical-performance-and-market-potential-drive-buy-rating 2024-11-05T21:25:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-s-atev-promising-clinical-performance-and-market-potential-drive-buy-rating 2024-11-05T21:25:41+00:00 weekly 0.7 https://trial.medpath.com/news/anaptys-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-05T21:18:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anaptys-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-05T21:18:07+00:00 weekly 0.7 https://trial.medpath.com/news/poseida-to-unveil-breakthrough-cancer-therapy-data-at-sitc-ash-2024-conferences 2024-11-05T21:10:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poseida-to-unveil-breakthrough-cancer-therapy-data-at-sitc-ash-2024-conferences 2024-11-05T21:10:25+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-05T21:08:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-05T21:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-reports-third-quarter-2024-financial-results-and-corporate-update 2024-11-05T21:05:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultragenyx-reports-third-quarter-2024-financial-results-and-corporate-update 2024-11-05T21:05:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-pushes-zenocutuzumab-decision-date-in-ngr1-nsclc-pdac-targeted-oncology 2024-11-05T20:49:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-pushes-zenocutuzumab-decision-date-in-ngr1-nsclc-pdac-targeted-oncology 2024-11-05T20:49:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-de-novo-authorization-to-photobiomodulation-device-for-dry-amd-healio 2024-11-05T20:44:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-de-novo-authorization-to-photobiomodulation-device-for-dry-amd-healio 2024-11-05T20:44:47+00:00 weekly 0.7 https://trial.medpath.com/news/kite-to-highlight-industry-leading-car-t-cell-therapy-portfolio-at-ash-2024-including 2024-11-05T20:30:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kite-to-highlight-industry-leading-car-t-cell-therapy-portfolio-at-ash-2024-including 2024-11-05T20:30:41+00:00 weekly 0.7 https://trial.medpath.com/news/highlights-in-prostate-cancer-treatment-advances-from-esmo-2024-ursula-vogl 2024-11-05T20:20:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/highlights-in-prostate-cancer-treatment-advances-from-esmo-2024-ursula-vogl 2024-11-05T20:20:38+00:00 weekly 0.7 https://trial.medpath.com/news/highlights-in-prostate-cancer-treatment-advances-from-esmo-2024-ursula-vogl 2024-11-05T20:16:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/highlights-in-prostate-cancer-treatment-advances-from-esmo-2024-ursula-vogl 2024-11-05T20:16:49+00:00 weekly 0.7 https://trial.medpath.com/news/amc-health-receives-expanded-fda-clearance-for-advanced-virtual-care-and-risk 2024-11-05T20:03:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amc-health-receives-expanded-fda-clearance-for-advanced-virtual-care-and-risk 2024-11-05T20:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-stock-flashes-a-surprise-entry-as-non-opioid-pain-drug-looms-investor-s-business-daily 2024-11-05T19:40:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-stock-flashes-a-surprise-entry-as-non-opioid-pain-drug-looms-investor-s-business-daily 2024-11-05T19:40:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-novel-combination-regimen-for-gi-cancers-the-asco-post 2024-11-05T19:38:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-novel-combination-regimen-for-gi-cancers-the-asco-post 2024-11-05T19:38:30+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-shows-slower-cognitive-decline-in-lower-tau-patients 2024-11-05T19:38:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-drug-shows-slower-cognitive-decline-in-lower-tau-patients 2024-11-05T19:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/genentech-to-present-blood-disorders-data-at-ash-markets-insider 2024-11-05T19:35:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genentech-to-present-blood-disorders-data-at-ash-markets-insider 2024-11-05T19:35:55+00:00 weekly 0.7 https://trial.medpath.com/news/ash24-novo-nordisk-takes-forma-s-sickle-cell-treatment-into-phase-3-endpoints-news 2024-11-05T19:33:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ash24-novo-nordisk-takes-forma-s-sickle-cell-treatment-into-phase-3-endpoints-news 2024-11-05T19:33:09+00:00 weekly 0.7 https://trial.medpath.com/news/genomic-variations-associated-with-risk-and-protection-against-vincristine-induced-nature 2024-11-05T19:31:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genomic-variations-associated-with-risk-and-protection-against-vincristine-induced-nature 2024-11-05T19:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/organon-fda-extends-vtama-atopic-dermatitis-review-to-march-morningstar 2024-11-05T19:25:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/organon-fda-extends-vtama-atopic-dermatitis-review-to-march-morningstar 2024-11-05T19:25:27+00:00 weekly 0.7 https://trial.medpath.com/news/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-product-in-pediatric-netherton 2024-11-05T19:13:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-product-in-pediatric-netherton 2024-11-05T19:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/organon-co-filed-sec-form-8-k-regulation-fd-disclosure-financial-statements-and-exhibits 2024-11-05T18:58:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/organon-co-filed-sec-form-8-k-regulation-fd-disclosure-financial-statements-and-exhibits 2024-11-05T18:58:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-envoy-medical-s-study-for-fully-implanted-cochlear-implant 2024-11-05T18:57:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-envoy-medical-s-study-for-fully-implanted-cochlear-implant 2024-11-05T18:57:17+00:00 weekly 0.7 https://trial.medpath.com/news/st-luke-s-surgeon-recognized-among-top-cited-scientists-saucon-source 2024-11-05T18:49:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/st-luke-s-surgeon-recognized-among-top-cited-scientists-saucon-source 2024-11-05T18:49:02+00:00 weekly 0.7 https://trial.medpath.com/news/journey-medical-s-emrosi-secures-fda-nod-for-rosacea-treatment 2024-11-05T18:37:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/journey-medical-s-emrosi-secures-fda-nod-for-rosacea-treatment 2024-11-05T18:37:27+00:00 weekly 0.7 https://trial.medpath.com/news/amc-health-receives-expanded-fda-clearance-for-advanced-virtual-care-and-risk 2024-11-05T18:27:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amc-health-receives-expanded-fda-clearance-for-advanced-virtual-care-and-risk 2024-11-05T18:27:55+00:00 weekly 0.7 https://trial.medpath.com/news/a-trial-of-vistusertib-and-paclitaxel-for-ovarian-cancer-that-has-come-back-octopus 2024-11-05T18:21:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-trial-of-vistusertib-and-paclitaxel-for-ovarian-cancer-that-has-come-back-octopus 2024-11-05T18:21:23+00:00 weekly 0.7 https://trial.medpath.com/news/sickle-cell-patient-dies-in-beam-study-of-base-editing-therapy-biopharma-dive 2024-11-05T18:13:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sickle-cell-patient-dies-in-beam-study-of-base-editing-therapy-biopharma-dive 2024-11-05T18:13:05+00:00 weekly 0.7 https://trial.medpath.com/news/new-momentum-for-a-time-limited-conditional-approval-pathway-for-rare-disease-drugs 2024-11-05T18:12:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-momentum-for-a-time-limited-conditional-approval-pathway-for-rare-disease-drugs 2024-11-05T18:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/case-study-shows-striking-improvements-in-patient-with-metastatic-prostate-cancer 2024-11-05T18:11:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/case-study-shows-striking-improvements-in-patient-with-metastatic-prostate-cancer 2024-11-05T18:11:07+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1-2-trial-of-del-brax-enrolling-new-possibly-pivotal-fshd-group-muscular-dystrophy-news 2024-11-05T18:09:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-1-2-trial-of-del-brax-enrolling-new-possibly-pivotal-fshd-group-muscular-dystrophy-news 2024-11-05T18:09:04+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-recor-medical-score-renal-denervation-reimbursement-wins-massdevice 2024-11-05T18:07:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-recor-medical-score-renal-denervation-reimbursement-wins-massdevice 2024-11-05T18:07:37+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-recor-win-cms-transitional-payment-coverage-for-renal-denervation-devices 2024-11-05T17:50:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-recor-win-cms-transitional-payment-coverage-for-renal-denervation-devices 2024-11-05T17:50:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-journey-medical-s-emrosi-for-rosacea-drug-topics 2024-11-05T17:31:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-journey-medical-s-emrosi-for-rosacea-drug-topics 2024-11-05T17:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-ablas-for-prolia-r-xgeva-r-biosimilars-from-organon-and-teva-venable-llp 2024-11-05T17:22:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-ablas-for-prolia-r-xgeva-r-biosimilars-from-organon-and-teva-venable-llp 2024-11-05T17:22:58+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-receives-fda-ok-for-orlynvah-drug-store-news 2024-11-05T17:19:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-receives-fda-ok-for-orlynvah-drug-store-news 2024-11-05T17:19:27+00:00 weekly 0.7 https://trial.medpath.com/news/ribomic-announces-positive-interim-results-from-phase-iia-trial-of-umedaptanib-pegol-in 2024-11-05T17:18:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ribomic-announces-positive-interim-results-from-phase-iia-trial-of-umedaptanib-pegol-in 2024-11-05T17:18:46+00:00 weekly 0.7 https://trial.medpath.com/news/sigmar1-activating-agent-blarcamesine-meets-pre-specified-efficacy-in-phase-2-3-trial-of 2024-11-05T17:11:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sigmar1-activating-agent-blarcamesine-meets-pre-specified-efficacy-in-phase-2-3-trial-of 2024-11-05T17:11:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-extends-review-period-for-zenocutuzumab-in-nrg1-pdac-nsclc 2024-11-05T17:07:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-extends-review-period-for-zenocutuzumab-in-nrg1-pdac-nsclc 2024-11-05T17:07:16+00:00 weekly 0.7 https://trial.medpath.com/news/dr-haggstrom-on-future-research-directions-in-egfr-and-alk-nsclc-onclive 2024-11-05T17:02:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-haggstrom-on-future-research-directions-in-egfr-and-alk-nsclc-onclive 2024-11-05T17:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/lucky-gene-therapy-break-for-daily-wage-earner-s-son-times-of-india 2024-11-05T17:01:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lucky-gene-therapy-break-for-daily-wage-earner-s-son-times-of-india 2024-11-05T17:01:05+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-to-help-patients-undergoing-cancer-immunotherapy-yale-school-of-medicine 2024-11-05T16:57:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-to-help-patients-undergoing-cancer-immunotherapy-yale-school-of-medicine 2024-11-05T16:57:28+00:00 weekly 0.7 https://trial.medpath.com/news/bolt-medical-announces-completion-of-restore-atk-and-restore-btk-pivotal-studies 2024-11-05T16:41:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bolt-medical-announces-completion-of-restore-atk-and-restore-btk-pivotal-studies 2024-11-05T16:41:09+00:00 weekly 0.7 https://trial.medpath.com/news/h-c-wainwright-rytelo-off-to-a-strong-launch-assigns-buy-to-geron-shares-investing-com 2024-11-05T16:31:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/h-c-wainwright-rytelo-off-to-a-strong-launch-assigns-buy-to-geron-shares-investing-com 2024-11-05T16:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-announces-positive-results-from-phase-3-essence-trial-of-semaglutide-2-4 2024-11-05T16:31:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-announces-positive-results-from-phase-3-essence-trial-of-semaglutide-2-4 2024-11-05T16:31:02+00:00 weekly 0.7 https://trial.medpath.com/news/damona-pharmaceuticals-given-fda-approval-for-trial-of-dpx-101-for-brain-disorders 2024-11-05T16:26:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/damona-pharmaceuticals-given-fda-approval-for-trial-of-dpx-101-for-brain-disorders 2024-11-05T16:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T16:25:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T16:25:43+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-journey-medical-s-rosacea-treatment-emrosi-pharmaceutical-technology 2024-11-05T16:20:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-journey-medical-s-rosacea-treatment-emrosi-pharmaceutical-technology 2024-11-05T16:20:54+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-and-innodia-partner-for-type-1-diabetes-awareness-and-patient-cision-news 2024-11-05T16:09:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-and-innodia-partner-for-type-1-diabetes-awareness-and-patient-cision-news 2024-11-05T16:09:21+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-and-innodia-partner-for-type-1-diabetes-awareness-and-patient 2024-11-05T16:05:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-and-innodia-partner-for-type-1-diabetes-awareness-and-patient 2024-11-05T16:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-and-innodia-partner-for-type-1-diabetes-awareness-and-patient-placera 2024-11-05T16:04:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-and-innodia-partner-for-type-1-diabetes-awareness-and-patient-placera 2024-11-05T16:04:52+00:00 weekly 0.7 https://trial.medpath.com/news/lyell-announces-presentation-of-initial-clinical-data-from-globenewswire 2024-11-05T15:49:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lyell-announces-presentation-of-initial-clinical-data-from-globenewswire 2024-11-05T15:49:57+00:00 weekly 0.7 https://trial.medpath.com/news/brief-overview-of-perseus-iskia-and-cassiopeia-clinical-trials-cancer-network 2024-11-05T15:34:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brief-overview-of-perseus-iskia-and-cassiopeia-clinical-trials-cancer-network 2024-11-05T15:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/native-hawaiians-pacific-islanders-found-to-be-underrepresented-in-clinical-trials 2024-11-05T15:34:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/native-hawaiians-pacific-islanders-found-to-be-underrepresented-in-clinical-trials 2024-11-05T15:34:17+00:00 weekly 0.7 https://trial.medpath.com/news/trials-update-our-q3-roundup-of-dementia-clinical-trials-news-being-patient 2024-11-05T15:29:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trials-update-our-q3-roundup-of-dementia-clinical-trials-news-being-patient 2024-11-05T15:29:14+00:00 weekly 0.7 https://trial.medpath.com/news/drap-launches-industry-e-reporting-system-to-monitor-drug-reaction-dental-news 2024-11-05T15:26:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drap-launches-industry-e-reporting-system-to-monitor-drug-reaction-dental-news 2024-11-05T15:26:35+00:00 weekly 0.7 https://trial.medpath.com/news/pioneering-clinical-trial-to-treat-cancer-in-patients-with-fanconi-anaemia-uab 2024-11-05T15:23:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pioneering-clinical-trial-to-treat-cancer-in-patients-with-fanconi-anaemia-uab 2024-11-05T15:23:41+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-markets-data 2024-11-05T15:07:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-markets-data 2024-11-05T15:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T15:05:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T15:05:50+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T14:58:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T14:58:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-dfd-29-for-treatment-of-adults-with-rosacea-related-inflammatory-lesions 2024-11-05T14:52:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-dfd-29-for-treatment-of-adults-with-rosacea-related-inflammatory-lesions 2024-11-05T14:52:01+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T14:51:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T14:51:58+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-placera 2024-11-05T14:49:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-placera 2024-11-05T14:49:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-extends-pdufa-date-for-zenocutuzumab-in-nrg1-nsclc-and-pancreatic-cancer 2024-11-05T14:47:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-extends-pdufa-date-for-zenocutuzumab-in-nrg1-nsclc-and-pancreatic-cancer 2024-11-05T14:47:26+00:00 weekly 0.7 https://trial.medpath.com/news/lyell-announces-presentation-of-initial-clinical-data-from-the-phase-1-2-clinical-trial-of 2024-11-05T14:46:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lyell-announces-presentation-of-initial-clinical-data-from-the-phase-1-2-clinical-trial-of 2024-11-05T14:46:36+00:00 weekly 0.7 https://trial.medpath.com/news/encouraging-data-revealed-for-schizophrenia-long-acting-injectables 2024-11-05T14:27:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/encouraging-data-revealed-for-schizophrenia-long-acting-injectables 2024-11-05T14:27:39+00:00 weekly 0.7 https://trial.medpath.com/news/roche-to-present-new-and-encouraging-long-term-follow-up-globenewswire 2024-11-05T14:26:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-to-present-new-and-encouraging-long-term-follow-up-globenewswire 2024-11-05T14:26:28+00:00 weekly 0.7 https://trial.medpath.com/news/genentech-to-present-new-and-encouraging-long-term-follow-up-data-across-morningstar 2024-11-05T14:23:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genentech-to-present-new-and-encouraging-long-term-follow-up-data-across-morningstar 2024-11-05T14:23:55+00:00 weekly 0.7 https://trial.medpath.com/news/ark-clinical-research-s-new-mobile-unit-pioneering-decentralized-clinical-morningstar 2024-11-05T14:23:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ark-clinical-research-s-new-mobile-unit-pioneering-decentralized-clinical-morningstar 2024-11-05T14:23:50+00:00 weekly 0.7 https://trial.medpath.com/news/genentech-to-present-new-and-encouraging-long-term-follow-up-data-across-broad 2024-11-05T14:23:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genentech-to-present-new-and-encouraging-long-term-follow-up-data-across-broad 2024-11-05T14:23:10+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-to-present-breakthrough-btk-degrader-data-at-ash-clinical-trial-results-revealed 2024-11-05T14:20:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurix-to-present-breakthrough-btk-degrader-data-at-ash-clinical-trial-results-revealed 2024-11-05T14:20:06+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-to-present-breakthrough-phase-3-results-for-jaypirca-at-ash-annual-meeting 2024-11-05T14:10:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-to-present-breakthrough-phase-3-results-for-jaypirca-at-ash-annual-meeting 2024-11-05T14:10:24+00:00 weekly 0.7 https://trial.medpath.com/news/onclive-s-october-roundup-of-key-fda-approvals-in-oncology 2024-11-05T14:08:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/onclive-s-october-roundup-of-key-fda-approvals-in-oncology 2024-11-05T14:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/ark-clinical-research-s-new-mobile-unit-pioneering-decentralized-clinical-yahoo-finance 2024-11-05T14:06:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ark-clinical-research-s-new-mobile-unit-pioneering-decentralized-clinical-yahoo-finance 2024-11-05T14:06:02+00:00 weekly 0.7 https://trial.medpath.com/news/nuvectis-pharma-inc-sec-10-q-report-tradingview 2024-11-05T14:03:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nuvectis-pharma-inc-sec-10-q-report-tradingview 2024-11-05T14:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/karyopharm-reports-third-quarter-2024-financial-results-and-highlights-recent-company-progress 2024-11-05T13:56:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/karyopharm-reports-third-quarter-2024-financial-results-and-highlights-recent-company-progress 2024-11-05T13:56:48+00:00 weekly 0.7 https://trial.medpath.com/news/a-potent-intramolecular-nlrp3-glue-inhibitor-advancing-through-multiple-phase-ii-trials 2024-11-05T13:43:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-potent-intramolecular-nlrp3-glue-inhibitor-advancing-through-multiple-phase-ii-trials 2024-11-05T13:43:11+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-fasenra-approved-by-ec-to-treat-rare-inflammatory-disease-egpa-pmlive 2024-11-05T13:37:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-fasenra-approved-by-ec-to-treat-rare-inflammatory-disease-egpa-pmlive 2024-11-05T13:37:35+00:00 weekly 0.7 https://trial.medpath.com/news/ema-accepts-marketing-authorization-application-for-biosimilar-to-simponi 2024-11-05T13:31:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-accepts-marketing-authorization-application-for-biosimilar-to-simponi 2024-11-05T13:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-product-in-pediatric-netherton 2024-11-05T13:17:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-product-in-pediatric-netherton 2024-11-05T13:17:46+00:00 weekly 0.7 https://trial.medpath.com/news/imugene-says-bile-tract-cancer-patient-maintains-complete-response-in-mast-study-biotech 2024-11-05T13:13:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imugene-says-bile-tract-cancer-patient-maintains-complete-response-in-mast-study-biotech 2024-11-05T13:13:56+00:00 weekly 0.7 https://trial.medpath.com/news/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-globenewswire 2024-11-05T13:13:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-globenewswire 2024-11-05T13:13:44+00:00 weekly 0.7 https://trial.medpath.com/news/ankyra-therapeutics-announces-first-visceral-tumor-patient-dosed-in-phase-1-anchor 2024-11-05T13:09:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ankyra-therapeutics-announces-first-visceral-tumor-patient-dosed-in-phase-1-anchor 2024-11-05T13:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/insignis-therapeutics-receives-positive-fda-feedback-on-in-001-clinical-program-for 2024-11-05T13:09:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insignis-therapeutics-receives-positive-fda-feedback-on-in-001-clinical-program-for 2024-11-05T13:09:30+00:00 weekly 0.7 https://trial.medpath.com/news/quoin-s-qrx003-shows-promise-in-pediatric-netherton-syndrome-trial-expansion-stock-titan 2024-11-05T13:05:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quoin-s-qrx003-shows-promise-in-pediatric-netherton-syndrome-trial-expansion-stock-titan 2024-11-05T13:05:30+00:00 weekly 0.7 https://trial.medpath.com/news/new-coalition-launches-to-transform-cancer-supportive-care-delivery-nationwide 2024-11-05T13:00:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-coalition-launches-to-transform-cancer-supportive-care-delivery-nationwide 2024-11-05T13:00:35+00:00 weekly 0.7 https://trial.medpath.com/news/ema-accepts-alvotech-and-advanz-pharma-s-avt05-maa-yahoo-finance 2024-11-05T12:40:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-accepts-alvotech-and-advanz-pharma-s-avt05-maa-yahoo-finance 2024-11-05T12:40:39+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-therapeutics-receives-fda-clearance-to-initiate-phase-ii-gloria-study-in-the-u-s 2024-11-05T12:39:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phaxiam-therapeutics-receives-fda-clearance-to-initiate-phase-ii-gloria-study-in-the-u-s 2024-11-05T12:39:42+00:00 weekly 0.7 https://trial.medpath.com/news/intra-cellular-therapies-announces-positive-topline-results-in-phase-3-trial-evaluating 2024-11-05T12:37:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intra-cellular-therapies-announces-positive-topline-results-in-phase-3-trial-evaluating 2024-11-05T12:37:24+00:00 weekly 0.7 https://trial.medpath.com/news/ac-immune-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update 2024-11-05T12:37:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ac-immune-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update 2024-11-05T12:37:22+00:00 weekly 0.7 https://trial.medpath.com/news/delta-fly-pharma-inc-update-for-expanded-phase-i-study-of-dfp-14927-afp-com 2024-11-05T12:34:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delta-fly-pharma-inc-update-for-expanded-phase-i-study-of-dfp-14927-afp-com 2024-11-05T12:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/zyversa-s-breakthrough-new-data-shows-promise-for-type-2-diabetes-prevention-zvsa-stock 2024-11-05T12:33:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zyversa-s-breakthrough-new-data-shows-promise-for-type-2-diabetes-prevention-zvsa-stock 2024-11-05T12:33:09+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw191-biospace 2024-11-05T12:21:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw191-biospace 2024-11-05T12:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/philips-enrolls-first-patient-in-u-s-clinical-trial-for-innovative-integrated-single-device-to-treat 2024-11-05T12:21:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/philips-enrolls-first-patient-in-u-s-clinical-trial-for-innovative-integrated-single-device-to-treat 2024-11-05T12:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/angitia-biopharmaceuticals-announces-dosing-of-first-patient-in-phase-2-clinical-trial-of 2024-11-05T12:21:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/angitia-biopharmaceuticals-announces-dosing-of-first-patient-in-phase-2-clinical-trial-of 2024-11-05T12:21:05+00:00 weekly 0.7 https://trial.medpath.com/news/national-hiv-drug-resistance-surveillance-among-adults-with-viral-non-suppression-in-south-africa 2024-11-05T12:21:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/national-hiv-drug-resistance-surveillance-among-adults-with-viral-non-suppression-in-south-africa 2024-11-05T12:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/germany-announces-2-further-planned-adult-use-cannabis-trials-but-legislation-not-yet 2024-11-05T12:18:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/germany-announces-2-further-planned-adult-use-cannabis-trials-but-legislation-not-yet 2024-11-05T12:18:24+00:00 weekly 0.7 https://trial.medpath.com/news/ema-accepts-alvotech-and-advanz-pharma-s-avt05-maa-pharmaceutical-technology 2024-11-05T12:14:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-accepts-alvotech-and-advanz-pharma-s-avt05-maa-pharmaceutical-technology 2024-11-05T12:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/itci-s-caplyta-shows-breakthrough-63-reduction-in-schizophrenia-relapse-risk 2024-11-05T12:13:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/itci-s-caplyta-shows-breakthrough-63-reduction-in-schizophrenia-relapse-risk 2024-11-05T12:13:51+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-bolsters-obesity-pipeline-with-promising-early-data-for-candidates-biospace 2024-11-05T12:12:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-bolsters-obesity-pipeline-with-promising-early-data-for-candidates-biospace 2024-11-05T12:12:45+00:00 weekly 0.7 https://trial.medpath.com/news/s93-phase-3-notus-trial-dupilumab-efficacy-and-safety-in-patients-with-moderate-to-severe 2024-11-05T11:58:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/s93-phase-3-notus-trial-dupilumab-efficacy-and-safety-in-patients-with-moderate-to-severe 2024-11-05T11:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/how-3d-printing-could-transform-solid-oral-dosage-forms-the-medicine-maker 2024-11-05T11:34:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-3d-printing-could-transform-solid-oral-dosage-forms-the-medicine-maker 2024-11-05T11:34:27+00:00 weekly 0.7 https://trial.medpath.com/news/how-hybrid-models-and-tech-are-shaping-the-future-of-clinical-research 2024-11-05T11:29:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-hybrid-models-and-tech-are-shaping-the-future-of-clinical-research 2024-11-05T11:29:34+00:00 weekly 0.7 https://trial.medpath.com/news/how-this-clinical-trial-could-help-alzheimer-s-patients-wptv 2024-11-05T11:20:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-this-clinical-trial-could-help-alzheimer-s-patients-wptv 2024-11-05T11:20:46+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw191-in 2024-11-05T11:12:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw191-in 2024-11-05T11:12:58+00:00 weekly 0.7 https://trial.medpath.com/news/why-treatments-can-fail-folks-with-wet-macular-degeneration-and-what-might-really-work 2024-11-05T11:11:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-treatments-can-fail-folks-with-wet-macular-degeneration-and-what-might-really-work 2024-11-05T11:11:26+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-service-vertex-reports-third-quarter-2024-financial-results 2024-11-05T11:03:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-service-vertex-reports-third-quarter-2024-financial-results 2024-11-05T11:03:49+00:00 weekly 0.7 https://trial.medpath.com/news/the-reliever-reliance-test-evaluating-a-new-tool-to-address-saba-over-reliance-nature 2024-11-05T10:58:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-reliever-reliance-test-evaluating-a-new-tool-to-address-saba-over-reliance-nature 2024-11-05T10:58:47+00:00 weekly 0.7 https://trial.medpath.com/news/interleukin-6-receptor-antibodies-tocilizumab-in-acute-myocardial-infarction-with-trials 2024-11-05T10:45:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/interleukin-6-receptor-antibodies-tocilizumab-in-acute-myocardial-infarction-with-trials 2024-11-05T10:45:57+00:00 weekly 0.7 https://trial.medpath.com/news/northwest-ehealth-nweh-announces-a-pilot-to-test-a-new-model-for-finding-and-recruiting 2024-11-05T10:29:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/northwest-ehealth-nweh-announces-a-pilot-to-test-a-new-model-for-finding-and-recruiting 2024-11-05T10:29:09+00:00 weekly 0.7 https://trial.medpath.com/news/how-this-clinical-trial-could-help-alzheimer-s-patients-wflx 2024-11-05T10:18:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-this-clinical-trial-could-help-alzheimer-s-patients-wflx 2024-11-05T10:18:30+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-prenatal-therapy-saves-children-with-congenital-vascular-malformations 2024-11-05T10:13:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-prenatal-therapy-saves-children-with-congenital-vascular-malformations 2024-11-05T10:13:33+00:00 weekly 0.7 https://trial.medpath.com/news/neuropace-announces-fda-submission-of-three-year-data-from-post-approval-study-of 2024-11-05T10:07:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuropace-announces-fda-submission-of-three-year-data-from-post-approval-study-of 2024-11-05T10:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/leading-cancer-centers-form-ai-alliance-with-40m-tech-industry-backing-to-revolutionize-cancer-research 2024-11-05T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leading-cancer-centers-form-ai-alliance-with-40m-tech-industry-backing-to-revolutionize-cancer-research 2024-11-05T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alvotech-and-teva-announce-fda-approval-of-additional-presentation-for-ustekinumab-biosimilar 2024-11-05T09:56:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alvotech-and-teva-announce-fda-approval-of-additional-presentation-for-ustekinumab-biosimilar 2024-11-05T09:56:49+00:00 weekly 0.7 https://trial.medpath.com/news/janus-kinase-jak-inhibitors-pipeline-assessment-2024-ema-openpr-com 2024-11-05T09:54:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/janus-kinase-jak-inhibitors-pipeline-assessment-2024-ema-openpr-com 2024-11-05T09:54:23+00:00 weekly 0.7 https://trial.medpath.com/news/photocure-partner-asieris-announces-marketing-approval-by-the-national-medical-products 2024-11-05T09:44:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/photocure-partner-asieris-announces-marketing-approval-by-the-national-medical-products 2024-11-05T09:44:58+00:00 weekly 0.7 https://trial.medpath.com/news/qyuns-therapeutics-drug-approval-boosts-market-presence-tipranks-com 2024-11-05T09:43:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qyuns-therapeutics-drug-approval-boosts-market-presence-tipranks-com 2024-11-05T09:43:18+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-confirms-acceptance-of-marketing-authorization-pipelinereview 2024-11-05T09:13:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-medicines-agency-confirms-acceptance-of-marketing-authorization-pipelinereview 2024-11-05T09:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/november-5-2024-study-snapshot-and-updated-ethics-documentation-available-for-moms 2024-11-05T09:05:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/november-5-2024-study-snapshot-and-updated-ethics-documentation-available-for-moms 2024-11-05T09:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/eligibility-and-endpoints-for-clinical-trials-in-trimodality-therapy-for-bladder-cancer 2024-11-05T09:02:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eligibility-and-endpoints-for-clinical-trials-in-trimodality-therapy-for-bladder-cancer 2024-11-05T09:02:12+00:00 weekly 0.7 https://trial.medpath.com/news/oak-hill-bio-and-chiesi-s-ohb-607-trial-enrols-first-european-subject-for-bpd-prevention 2024-11-05T09:00:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oak-hill-bio-and-chiesi-s-ohb-607-trial-enrols-first-european-subject-for-bpd-prevention 2024-11-05T09:00:35+00:00 weekly 0.7 https://trial.medpath.com/news/who-launches-new-clinical-trials-guidance-what-do-i-need-to-know 2024-11-05T08:51:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-launches-new-clinical-trials-guidance-what-do-i-need-to-know 2024-11-05T08:51:31+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-jmt103-in-patients-with-unresectable-or-surgically-challenging-giant-nature 2024-11-05T07:38:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-jmt103-in-patients-with-unresectable-or-surgically-challenging-giant-nature 2024-11-05T07:38:52+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-confirms-acceptance-of-marketing-authorization-application 2024-11-05T07:21:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-medicines-agency-confirms-acceptance-of-marketing-authorization-application 2024-11-05T07:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-s-freestyle-libre-cgm-systems-receive-first-ever-approval-for-use-during-medical-imaging-as-semaglutide-supply-stabilizes 2024-11-05T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbott-s-freestyle-libre-cgm-systems-receive-first-ever-approval-for-use-during-medical-imaging-as-semaglutide-supply-stabilizes 2024-11-05T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hookipa-pharma-s-swot-analysis-stock-s-potential-in-immunotherapy-market 2024-11-05T06:41:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hookipa-pharma-s-swot-analysis-stock-s-potential-in-immunotherapy-market 2024-11-05T06:41:57+00:00 weekly 0.7 https://trial.medpath.com/news/uk-government-partners-with-oxford-nanopore-to-launch-nhs-wide-pathogen-surveillance-system 2024-11-05T06:20:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-government-partners-with-oxford-nanopore-to-launch-nhs-wide-pathogen-surveillance-system 2024-11-05T06:20:04+00:00 weekly 0.7 https://trial.medpath.com/news/medical-moment-new-fda-approved-implants-for-shoulder-replacements-wndu 2024-11-05T06:15:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medical-moment-new-fda-approved-implants-for-shoulder-replacements-wndu 2024-11-05T06:15:40+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-combo-shows-promising-results-in-high-risk-cervical-cancer 2024-11-05T06:01:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pembrolizumab-combo-shows-promising-results-in-high-risk-cervical-cancer 2024-11-05T06:01:47+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-gap-in-masld-related-liver-cancer-screening-26-of-non-cirrhotic-cases-show-low-fib-4-scores 2024-11-05T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-gap-in-masld-related-liver-cancer-screening-26-of-non-cirrhotic-cases-show-low-fib-4-scores 2024-11-05T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-yahoo-finance 2024-11-05T05:56:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-yahoo-finance 2024-11-05T05:56:14+00:00 weekly 0.7 https://trial.medpath.com/news/first-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-pr-newswire 2024-11-05T05:51:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-pr-newswire 2024-11-05T05:51:42+00:00 weekly 0.7 https://trial.medpath.com/news/ncats-award-will-support-multi-site-study-to-evaluate-remote-trials-university-at-buffalo 2024-11-05T05:42:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ncats-award-will-support-multi-site-study-to-evaluate-remote-trials-university-at-buffalo 2024-11-05T05:42:07+00:00 weekly 0.7 https://trial.medpath.com/news/biocity-presents-late-breaking-clinical-trial-results-with-sc0062-for-iga-nephropathy-at-asn 2024-11-05T05:40:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocity-presents-late-breaking-clinical-trial-results-with-sc0062-for-iga-nephropathy-at-asn 2024-11-05T05:40:18+00:00 weekly 0.7 https://trial.medpath.com/news/northwest-ehealth-nweh-announces-a-pilot-to-test-a-new-model-for-finding-and-recruiting 2024-11-05T05:14:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/northwest-ehealth-nweh-announces-a-pilot-to-test-a-new-model-for-finding-and-recruiting 2024-11-05T05:14:32+00:00 weekly 0.7 https://trial.medpath.com/news/iron-chelator-deferiprone-shows-adverse-effects-in-early-alzheimer-s-disease-trial 2024-11-05T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iron-chelator-deferiprone-shows-adverse-effects-in-early-alzheimer-s-disease-trial 2024-11-05T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/world-s-first-drug-to-regrow-teeth-is-now-in-clinical-trials-the-brighter-side-of-news 2024-11-05T04:48:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-s-first-drug-to-regrow-teeth-is-now-in-clinical-trials-the-brighter-side-of-news 2024-11-05T04:48:41+00:00 weekly 0.7 https://trial.medpath.com/news/lumithera-obtains-fda-authorization-of-valeda-treatment-for-dry-amd-patients-to-improve-vision 2024-11-05T04:35:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lumithera-obtains-fda-authorization-of-valeda-treatment-for-dry-amd-patients-to-improve-vision 2024-11-05T04:35:01+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-reports-strong-q3-launch-for-copd-drug-tipranks-com 2024-11-05T04:20:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verona-pharma-reports-strong-q3-launch-for-copd-drug-tipranks-com 2024-11-05T04:20:48+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-inc-announces-fda-clearance-of-its-phase-ii-oncology-trial-marketscreener 2024-11-05T03:26:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytodyn-inc-announces-fda-clearance-of-its-phase-ii-oncology-trial-marketscreener 2024-11-05T03:26:48+00:00 weekly 0.7 https://trial.medpath.com/news/ribomic-announces-positive-interim-results-from-phase-iia-trial-of-umedaptanib-pegol-in-achondroplasia 2024-11-05T03:11:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ribomic-announces-positive-interim-results-from-phase-iia-trial-of-umedaptanib-pegol-in-achondroplasia 2024-11-05T03:11:38+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-pharmaceuticals-vrtx-q3-2024-earnings-call-transcript-the-globe-and-mail 2024-11-05T02:42:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-vrtx-q3-2024-earnings-call-transcript-the-globe-and-mail 2024-11-05T02:42:03+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-or-bust-big-pharma-s-surprising-moves-jomfruland-net 2024-11-05T02:34:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-or-bust-big-pharma-s-surprising-moves-jomfruland-net 2024-11-05T02:34:54+00:00 weekly 0.7 https://trial.medpath.com/news/xencor-doses-first-subject-in-phase-1-2-study-of-xmab-r-942-in-development-for-patients 2024-11-05T02:14:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xencor-doses-first-subject-in-phase-1-2-study-of-xmab-r-942-in-development-for-patients 2024-11-05T02:14:45+00:00 weekly 0.7 https://trial.medpath.com/news/sana-biotechnology-pivots-to-autoimmune-focus-announces-layoffs-and-pipeline-restructuring 2024-11-05T01:40:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sana-biotechnology-pivots-to-autoimmune-focus-announces-layoffs-and-pipeline-restructuring 2024-11-05T01:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/recce-says-patient-dosing-in-phase-2-clinical-trial-advances-to-final-stages-biotech 2024-11-05T01:34:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-says-patient-dosing-in-phase-2-clinical-trial-advances-to-final-stages-biotech 2024-11-05T01:34:01+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-announces-key-takeaways-from-oral-presentations-at-the-17th-clinical-trials-on 2024-11-05T01:26:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cervomed-announces-key-takeaways-from-oral-presentations-at-the-17th-clinical-trials-on 2024-11-05T01:26:31+00:00 weekly 0.7 https://trial.medpath.com/news/niagara-trial-shows-durvalumab-plus-chemotherapy-improves-survival-in-muscle 2024-11-05T01:26:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/niagara-trial-shows-durvalumab-plus-chemotherapy-improves-survival-in-muscle 2024-11-05T01:26:12+00:00 weekly 0.7 https://trial.medpath.com/news/nationwide-epilepsy-clinical-trial-investigates-potential-new-treatment-the-rochelle-news-leader 2024-11-05T01:13:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nationwide-epilepsy-clinical-trial-investigates-potential-new-treatment-the-rochelle-news-leader 2024-11-05T01:13:45+00:00 weekly 0.7 https://trial.medpath.com/news/merus-receives-fda-extension-of-pdufa-for-zenocutuzumab 2024-11-05T01:11:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merus-receives-fda-extension-of-pdufa-for-zenocutuzumab 2024-11-05T01:11:36+00:00 weekly 0.7 https://trial.medpath.com/news/quantatm-dialysis-system-receives-fda-clearance-for-home-hemodialysis 2024-11-05T00:52:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quantatm-dialysis-system-receives-fda-clearance-for-home-hemodialysis 2024-11-05T00:52:34+00:00 weekly 0.7 https://trial.medpath.com/news/5-year-follow-up-of-the-phase-2-optic-study-in-patients-with-chronic-phase-chronic-myeloid-leukemia 2024-11-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-year-follow-up-of-the-phase-2-optic-study-in-patients-with-chronic-phase-chronic-myeloid-leukemia 2024-11-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-type-1-diabetes-reprogramming-fat-cells-to-restore-insulin-production 2024-11-04T23:59:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-type-1-diabetes-reprogramming-fat-cells-to-restore-insulin-production 2024-11-04T23:59:55+00:00 weekly 0.7 https://trial.medpath.com/news/guess-which-asx-300-stock-is-jumping-11-on-big-news-motley-fool 2024-11-04T23:32:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/guess-which-asx-300-stock-is-jumping-11-on-big-news-motley-fool 2024-11-04T23:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ide-for-akura-medical-s-thrombectomy-system-massdevice 2024-11-04T23:28:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ide-for-akura-medical-s-thrombectomy-system-massdevice 2024-11-04T23:28:19+00:00 weekly 0.7 https://trial.medpath.com/news/neuraxis-wins-expanded-fda-clearance-for-non-implanted-neurostim-for-pain-relief 2024-11-04T23:28:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuraxis-wins-expanded-fda-clearance-for-non-implanted-neurostim-for-pain-relief 2024-11-04T23:28:19+00:00 weekly 0.7 https://trial.medpath.com/news/teva-shares-positive-phase-iii-data-of-schizophrenia-injectable-tev-749 2024-11-04T23:23:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-shares-positive-phase-iii-data-of-schizophrenia-injectable-tev-749 2024-11-04T23:23:49+00:00 weekly 0.7 https://trial.medpath.com/news/unity-biotechnology-inc-sec-10-q-report-tradingview 2024-11-04T23:16:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unity-biotechnology-inc-sec-10-q-report-tradingview 2024-11-04T23:16:21+00:00 weekly 0.7